Treatment of DNA damage response deficient cancers

A compound of formula I addresses the challenge of treating cancers with DNA damage response deficiencies by inducing cytotoxicity and suppressing tumor progression, particularly in cancers with replication stress.

WO2026240707A1PCT designated stage Publication Date: 2026-11-19NANYANG BIOLOGICS PTE LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/SG2026/050300
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2025-05-15
Filing Date
2026-05-14
Publication Date
2026-11-19

AI Technical Summary

Technical Problem

There is a need for improved methods to treat cancers characterized by defects in DNA damage response pathways, which exhibit genomic instability and altered sensitivity to therapeutic intervention.

Method used

Administering a compound of formula I, or its pharmaceutically acceptable salt or solvate, to subjects with DNA damage response deficient cancers, targeting specific biomarkers to enhance treatment efficacy.

Benefits of technology

The compound effectively induces cytotoxicity and suppresses tumor progression in DNA damage response deficient cancers, demonstrating synergistic effects with DNA-damaging agents and selectively targeting replication stress.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure SG2026050300_19112026_PF_FP_ABST
    Figure SG2026050300_19112026_PF_FP_ABST
Patent Text Reader

Abstract

Disclosed are methods of treating a DNA damage response deficient cancer in a subject, the method comprises administering an effective amount of a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, to the subject, wherein R1 and R2 are defined herein.
Need to check novelty before this filing date? Find Prior Art

Description

TREATMENT OF DNA DAMAGE RESPONSE DEFICIENT CANCERSCROSS-REFERENCE TO RELATED APPLICATION

[0001] This application claims the priority benefit of Singapore Application No. 10202501254T, filed on 15 May 2025, which is hereby incorporated by reference in its entirety.FIELD OF INVENTION

[0002] The present invention relates generally to the field of cancer therapeutics and, more specifically, to the use of certain molephantin compounds, including compounds of Formula I and pharmaceutical compositions thereof, for the treatment of cancer, in particular cancers characterized by defects in DNA damage response pathways or other biomarkers associated with treatment response.BACKGROUND OF INVENTION

[0003] Cancer remains a major cause of morbidity and mortality worldwide, and many cancers continue to be difficult to treat despite advances in surgery, radiotherapy, chemotherapy, targeted therapy, and immunotherapy.

[0004] A substantial proportion of cancers are characterized by defects in DNA damage response pathways. Such pathways are involved in detecting, signalling, repairing, or tolerating DNA damage and replication-associated stress. Cancers having defects in DNA damage response pathways may exhibit genomic instability and may display altered sensitivity to therapeutic intervention.

[0005] Therefore, there remains a need for improved methods for treating cancers characterized by DNA damage response deficiency or related response-associated biomarkers.SUMMARY OF INVENTION

[0006] In one aspect, the present disclosure provides a method of treating a DNA damage response deficient cancer in a subject, the method comprising administering an effective amount of a compound of formula I, or a pharmaceutically acceptable salt or solvate thereof, to the subject,where R1and R2each independently represent H, -C(O)R3or -C(O)Ci-e alkyl, which latter group is unsubstituted or substituted by one or more groups selected from halo and R4, or R1represents -C(O)R3or -C(O)Ci-e alkyl, which latter group is unsubstituted or substituted by one or more groups selected from halo and R4, and R2represents -C(O)C(=CH2)CH3;R3, when present, represents aryl, cycloalkyl ora heterocyclic ring system, where each of aryl, cycloalkyl and the heterocyclic ring system is unsubstituted or substituted by one or more groups selected from halo, Ci-3 alkyl, and NO2, where C1-3 alkyl is unsubstituted or substituted by one or more halo groups; R4, when present, represents aryl, cycloalkyl ora heterocyclic ring system, where each of aryl, cycloalkyl and the heterocyclic ring system is unsubstituted or substituted by one or more groups selected from halo and C1-3 alkyl, where C1-3 alkyl is unsubstituted or substituted by one or more halo groups.DESCRIPTION OF FIGURES

[0007] The accompanying figures illustrate disclosed embodiments of the invention and serve to explain the principles of the disclosed embodiments. It is to be understood, however, that the figures are designed for purposes of illustration only, and not as a definition of the limits of the invention.

[0008] Figure 1: Identification of Molephantin revealed selective cytotoxicity in solid cancers. (A) Sankey plot of recruited cancer patients (n = 7) in a retrospective observational study on integrative medicine (B) Progression of PSA level in naive stage IV metastatic prostate cancer patients receiving integrative medicine. (C) CT scan of a naive prostate cancer patient before and five months after receiving integrative medicine. 'P' denotes the region of the prostate, and T indicates the region of the tumor. (D) Overall view of individual patients receiving integrative medicine, which comprised a minimum daily oral administration of combined PAs for a minimum period of six months. (E) Cell generation was tracked by measuring the fluorescence intensity of CFSE-labelled DLD1 cells treated with vehicle (DMSO) or 0.5, 5, and 50 pg / ml of various PAs for 96 hours. “Parental” CFSE-labelled cells at day 0 were used as the reference for maximum fluorescence intensity in flow cytometry analysis (n = 3). (F) A simplified schematic of extract production was generated using various parts of Elephantopus tomentosus L., as indicated (left). Cell proliferation was determined at 48 and 72 hours after DLD1 cells received increasing concentration (0 - 1.70 mg / ml) of extract treatment (n = 3). (G) Isolation of Molephantin and Molephantinin compounds from young leaf extracts by preparative HPLC. (H) Chemical structures of Molephantin (NYH001) and Molephantinin (NYH101), and their dose-response effects in DLD1 cells. ECso values were determined 48 hours after treatment (n = 3). (I) Cancer-specific cytotoxicity as revealed in a panel of tumorigenic (n = 10) and non-cancerous (n = 1) cell lines treated with a dose range of 0.1 - 10 itM of NYH001 for 48 hours. Data were presented as the average ECso (n = 3). (J, K) Nude mice were engrafted with 1 x 106HCT 116 cells, followed by intraperitoneal treatment with either vehicle or 25 mg / kg of NYH001. Treatment was performed every other day for two weeks with the animals’ weight measured daily. A control cull was executed upon completion of treatment, and individual tumors were excised for assessment. Data are presented as mean ± SEM. Unpaired two-tailed t-test (I, J, and K). p-values of < 0.05 were considered significant.

[0009] Figure 2: Lead-optimized NYH002 suppresses replication machinery and causes chromosomal aberrations. (A) Structural analogue of NYH001 derivatives. (B) Dose-response of NYH001 derivatives (NYH002 - NYH006) in a panel of 10 different cancer cell lines as indicated. Mean survival was determined at 48 hours post-treatment (n = 3). (C) Therapeutic efficacy of NYH001 derivatives. Fold change in mean ECsowas assessed across 10 cell lines and presented as pan-cancer data at 48 hours post-treatment. Each derivative was compared to the corresponding NYH001 -treated cell line, where individual dot represents the mean ECsoof the respective cancer cell line (n = 3). (D) Evaluation of systemic cytotoxicity. A total of 21 healthy nude mice was randomly assigned to vehicle, NYH002 and NYH003 treatment arms. Each animal received a total of 14 daily intraperitoneal injections at 25 mg / kg for 2 weeks. Animal weights were recorded before and after treatment to assess animal health. (E) Drug-induced cell death in DLD1 cells following treatment with increasing concentrations of NYH001 and NYH002 (1 - 10 pM) for 24 hours. An immunoblot was performed with WCL to determine activation of apoptosis by cleavage of PARP, caspase-3, and caspase-7, p-tubulin was used as a loading control. (F) Pathway enrichment analysis of the downregulated proteome was performed on DLD1 cells treated with 2.5 pM NYH002 for 24 hours, followed by TMT-labelling of WCL for MS analysis (n = 3). Based on KEGG, Reactome, WikiPathways, and Gene Ontology databases, the differentially downregulated proteins were subjected to pathway enrichment analysis. (G) The protein-protein interaction (PPI) network of NYH002-treated DLD1 cells was established using the STRING and IntAct databases. The network was built on the downregulated proteome as the first interactors (primary clusters), followed by the integration of downregulated transcriptome data to identify the second interactors (secondary clusters). (H) Cell cycle profile based on the propidium iodide staining of DMSO-and 2.5 pM NYH002-treated DLD1 cells after 24 hours (n = 3). (I) Chromatid breaks in metaphase spread of DLD1 cells treated with DMSO or 2.5 pM NYH002 for 24 hours (n = 3). Scale bar: 5 pm. (J, K) Quantitative image-based cytometry of immunolabelled DLD1 cells receiving either DMSO or 2.5 pM NYH002 for 24 hours. Total number of - H2AX or 53BP1 foci and nuclear DAPI intensity were determined for each of >1 ,000 individual cells (n = 3). Data are presented as mean ± SEM. Unpaired two-tailed t-test (C, D and H), hypergeometric test with Bonferroni step-down (F) and Mann-Whitney U test (J and K). p-values of < 0.05 were considered significant whereas N.S was regarded as not significant.

[0010] Figure 3: NYH002 induces replication breakages via the collision of pathological R-loops. (A) A simplified schematic strategy to determine NYH002 localization in the cellular compartment (left). NYH002-alkyne (NYH002P) was enabled by click chemistry to function as a fluorescent probe. DLD1 cells were treated with 0.5 pM of this compound and fixed at the indicated time points to determine NYH002P localization within the nuclear compartment. (B) Replication-induced fork breakage was assessed by synchronizing DLD1 cell at Gi / S-phase with APH or G2-phase with CDK1 inhibitor for 16 hours. Synchronized cells were released from these chemicals (APH-r and CDK1-r) and immediately received 2.5 pM of NYH002 treatment. DLD1 cells were fixed at one- and six-hours post-treatment and analyzed for DNA DSB by - H2AX foci count. (C) Replication fork stalling was assessed by quantifying the total number of ongoing DNA fiber (left) events and the lack of origin firing (right) in DLD1 cells treated with either DMSO or 2.5 pM NYH002 (n = 3). (D) Pile-up interaction at the TSS of genes withaltered or constant expression following NYH002 treatment (left), alongside a volcano plot showing RNA expression of the genes represented within the pile-up (right). The black dashed square indicates a region of increased interaction at the TSS of downregulated genes following 2.5 pM NYH002 treatment. (E) H i-C heatmap at 32kb resolution centered around the downregulated NFKB1 gene by NYH002 treatment showing distinct effect of chromatin condensation. (F) Transcript expression of NFKB1 gene in DLD1 cells was determined by RT-qPCR after 24 hours treatment with DMSO or 1 pM of NYH002 (n = 3). (G) Chromatin condensation was determined by H3K27m3 expression in the nucleus of DLD1 cells treated with DMSO or 1 pM of NYH002 for 24 hours (n = 3). Arrow in white indicates orientation of direction. Scale bar: 5 pm. (H) Immunoblot of transcription stalling in DLD1 cells treated with DMSO or 1 pM NYH002 for 24 hours, as determined by RNAPII, yH2AXand HP1 expression levels. GAPDH was used as loading control. (I) Presence of R-loops and their proximity to NYH002 localization were assessed 24 hours after treatment with 1 pM of the compound’s probe, followed by click chemistry with AF549 fluorophore and immunofluorescence staining using the S9.6 antibody in DLD1 cells. Arrow in white indicates orientation of direction. Scale bar: 5 pm. (J) Collision between replication and transcription machinery was determined by the co-localization events of RNAPII and yH2AX foci post-24 hours after treatment with DMSO or 1 pM NYH002 in DLD1 cells (n = 3). (K) Dissolution of TRC through transcription inhibition by DRB (50 pM) was carried out one hour prior to the treatment of 1 pM NYH002 in DLD1 cells. Cells were examined 24 hours later for the presence of DNA DSBs by quantifying total cell number with >5 - H2AX foci (n = 3). (L, M) Phenotypic profile of R-loops was assessed in DLD1 cells transfected with empty vector (EV), or RNaseHI for 24 hours, followed by treatment with 1 pM NYH002 for an additional 24 hours. Immunofluorescence staining was then performed using either the S9.6 or - / H2AX antibody. (N) Reduction in NYH002 efficacy was assessed in a dose-dependent manner in DLD1 and H1299 cells transfected with either RNaseHI to resolve R-loops or with an empty vector. Cell viability was measured 48 hours post-treatment and data were presented as mean ECso of NYH002 (n = 3). Data are presented as mean ± SEM. Mann-Whitney U test (A, L and M). Unpaired two-tailed t-test (B, C, J, K and N). p-values < 0.05 were considered significant whereas N.S was regarded as not significant.

[0011] Figure 4: Targeting the ILF2-DHX9 axis by NYH002 increases R-loop accumulation. (A, B) Competitive binding involved the initial treatment with NYH002 (2 pM) or DMSO for one hour, followed by the addition of NYH002P (1 pM) for an additional five hours. Click chemistry was performed between NYH002P and the AF647 fluorescent probe for immunofluorescence analysis in DLD1 cells, or alternatively with biotin for subsequent HRP-based detection in WCL by immunoblotting. (C) MS label-free quantification of gel-separated proteins was performed on NYH002P-biotin coimmunoprecipitation from DLD1 WCL. Direct (core) and indirect (accessory) drug-protein interactors were classified as either 'identified', which matched the expected molecular weight, or 'misidentified', which showed an incorrect molecular weight (n = 3). (D) NYH002P-protein interactome was curated using the nuclear complex dataset from CORUM followed by the construction of a PPI network with STRING. (E) Validation of NYH002-interacting proteins that were identified from the ‘DNA / RNA binding’ and 'Transcription' cluster in STRING. Co-immunoprecipitation was performed using click chemistrybetween NYH002P and biotin in DLD1 cells. Input represents 1% of the total WCL. (F) Competitive binding of NYH002P-interacting proteins was assessed by co-immunoprecipitation in DLD1 cells. Input represents 1% of the total WCL. (G) A simplified model based on AlphaFold3 prediction of the ILF2 protein complex. (H) Visualization of drug-protein interactions. PLA was carried out between the indicated proteins and post-treatment with NYH002P (1 pM) at six hours in DLD1 cells. Foci of PLA in the nucleus represent physical drug-protein interaction. LEF-1 nuclear protein was used as a negative control (n = 3). Scale bar: 10 pm. (I) Cellular thermal shift assay was employed to determine the direct interaction between NYH002 and ILF2. DMSO was used as a negative control (n = 3). (J, K) Immunoblot of the ILF2 complex revealed that treatment with 1 pM NYH002for24 hours in DLD1 cells phenocopied the effect of ILF2 depletion by siRNA. (L, M, N) Phenotypic characterization of R-loops in siRNA-mediated ILF2-depleted DLD1 cells at 48 hours post-transfection. Loss of ILF2 resulted in the induction of S9.6, ssDNA, and yH2AX foci (n = 3). Scale bar: 10 pm. (O, P) Immunoblot showing downregulation of DHX9, WRN, and SETX helicases as a direct consequence of ILF2 targeting by NYH002 (1 pM, 24 hours post-treatment) or by siRNA-mediated depletion (48 hours post-transfection). GAPDH was used as a loading control. (Q) Co-immunoprecipitation of NYH002P-biotin via click chemistry revealed a direct interaction with ILF2 and DHX9, but neither with WRN nor SETX. Input represents 1 % of the total WCL derived from DLD1 cells. (R) In silica STRING analysis indicated that the interaction of ILF2 with WRN and SETX is dependent on DHX9. (S) PLA in the nucleus of DLD1 cells showed direct interaction between ILF2 and DHX9 (n = 3). (T) siRNA-mediated ILF2 depletion in DLD1 cells resulted in a significant reduction in PLA foci formation between NYH002P and DHX9 (n = 3). Data are presented as mean ± SEM. Mann-Whitney U test (A, L and M), two-way ANOVA (I and T) and unpaired two-tailed t-test (N). p-values < 0.05 were considered significant.

[0012] Figure 5: NYH002 synergizes with DNA-damaging agents to suppress tumor progression and exhibits monotherapy efficacy against cancer cells with replication stress. (A) A series of dose-response matrices of NYH002 in combination with TMZ, 5-FU, or MMS. Synergy map showed the combination effects of DLD1 cell survival as indicated by SynergyFinder 3.0. A score of >10 indicates synergistic, <10 indicates additive, and <-10 indicates antagonistic. (B, C) Synergistic effect of NYH002 with TMZ, 5-FU, or MMS on the induction of DNA DSBs and apoptosis. DLD1 cells received 0.5 pM NYH002, 1.5 mM TMZ, 0.1 mM 5-FU, or 0.5 mM MMS as monotherapies or in combination, as indicated, for 24 hours prior to immunostaining for yH2AX. Alternatively, WCL were prepared for immunoblotting to examine cleaved caspase-3. Vinculin was used as a loading control. (D) Synergy of NYH002 and TMZ in vivo. Flank tumor implantation was performed by injecting 1 x 106cells into the subcutaneous space of the animals, followed by intraperitoneal dosing of NYH002 in combination with oral administration of TMZ for nine weeks. Tumor growth was monitored and measured daily. A control cull was performed at day 63. (E, F) Immunoblot of differential protein expression of CCNE1 and E2F1 as indicators for Gi / S checkpoint deficiency. MCF7 and MDA-MB436 cell lines represent a matched tumor pair for breast cancer, whereas U251 and U2OS serve as a non-paired tumor comprising of glioblastoma and osteosarcoma, respectively. Vinculin was used as a loading control. (G, H) Baseline replication stress is indicated by the presence of unresolved - H2AX as shown by the different cell lines (n = 3). (I, J) Increased susceptibility to replication-induced DSBs after treatment with 0.5 - 1.5 pM ofNYH002 for 24 hours was observed in MDA-MB436 and U2OS cells with Gi / S-phase checkpoint deficiency, as compared to MCF7 and U251 cells with normal cell cycle progression (n = 3). (K, L) ECso of NYH002 was determined after 48 hours in both paired-match (MCF7 and MDA-MB436) and nonpaired (U251 and U2OS) cell lines (n = 3). Data are presented as mean ± SEM. Mann-Whitney U test (B, G and H), two-way ANOVA (D) and one-way ANOVA (I and J), p-values < 0.05 were considered significant.

[0013] Figure 6: NYH002 therapy is lethal in HR deficient tumors. (A, B) Reproducibility of the siRNA DDR library screen for gene candidates (blue region). Spearman correlation was determined between the two independent replicates of Z-scores A and B in assessing the inhibition of DLD1 cell growth after 72 hours of treatment. The percentile ranking was based on the mean difference in growth inhibition between NYH002- and DMSO-treated DLD1 cells transduced with individual siRNA DDR gene candidates (n = 239). (C) STRING enrichment of the top 90thpercentile of gene candidates identified in the DDR response category. (D) siRNA-mediated depletion of HR gene transcripts, identified in the top 90thpercentile, was assessed 48 hours post-transfection by immunoblotting WCL of DLD1 cells. (E) Synergistic interaction between NYH002 and individual HR genes (EX01, MSH3, and FEN1) was assessed based on cell survival readout at 72 hours post-treatment and calculated using GDI. Genomic scar scores were selected for nine HR-proficient and one HRD cancer cell line, as indicated. GDI < 1 indicates synergistic (Syn), GDI = 1 indicates additive (Add), and GDI > 1 indicates antagonistic (Ant). (F) Dose response of NYH002 in the colony formation assay of HR-proficient (A549) and HRD (NCI-H1299) cell lines after seven days of treatment (n = 3). (G, H) Pharmacokinetics was determined by intraperitoneal administration of 25 mg / kg NYH002 in BALB / cJ mice, followed by a series of control cull at 2, 4, 8, 16, and 24 hours. Plasma and animal organs were processed and subsequently resuspended in ACN solution to precipitate NYH002 for detection and quantification by MS. (I, J, K) Cytotoxicity of NYH002 was assessed by administering either DMSO or 25 mg / kg NYH002 via intraperitoneal injection into nude mice on alternate days for two weeks, followed by a control cull to collect whole blood for hematologic viability analysis. The kidney and liver were also fixed and processed for H&E staining to assess changes in tissue architecture and the presence of necrotic cells.(L, M) Assessment of NYH002 therapeutic efficacy in xenograft lung cancer models. Nude mice were randomly assigned and implanted with 1 x 106HR-proficient (A549) or HRD (NCI-H1299) cells into the subcutaneous space of the animal’s flank. T reatment was subsequently administered as either vehicle or 25 mg / kg NYH002 via intratumoral injection. Tumor size was measured alternate days for a period of two weeks. A control cull was performed upon completion of the treatment regimen. (N, O) Therapeutic assessment of NYH002 in orthotopic breast cancer models. Nude mice were randomly assigned and implanted with 1 x 106of HR-proficient (MDA-MB231) and HRD (MDA-MB436) cells in the mammary fat pad. Treatment was subsequently administered as either vehicle or 25 mg / kg NYH002 via intraperitoneal injection. T umor size was measured every alternate day for two weeks. A control cull was performed upon completion of the treatment regimen. Data are presented as mean ± SEM. Unpaired two-tailed t-test (E and I) and two-way ANOVA (L, M, N and O). p-values < 0.05 were considered significant whereas N.S was regarded as not significant.

[0014] Figure 7: A proposed model of NYH002. (A, B) Therapeutic framework illustrating the mechanisms of action of NYH002. Created with BioRender.com.

[0015] Figure 8: Discovery of NYH001 and NYH101 compounds in patient cohort receiving integrative medicine. (A) Flowchart of patient recruitment for eligibility and inclusion in the retrospective observational study. (B) T1 -weighted MRI scans of patient 00-13 before and after receiving integrated therapy. (C) Hazard ratio (HR) of glioblastoma patients from the TCGA database in comparison to the existing survival timeline (alive) of patient 00-13. (D)1H NMR structural information of the naturally occurring NYH001 (Molephantin) and NYH101 (Molephantinin). (E) Dose response of NYH001 and NYH101 in DLD1 cells at 72 hours post-treatment (n = 3). Data are presented as mean ± SEM.

[0016] Figure 9: Lead-optimized NYH001 suppresses the replication machinery leading to chromosomal aberrations. (A) An overview of the strategy used for the derivatization of Molephantin molecules. (B)1H NMR structural information of Molephantin derivatives (NYH002 - NYH006). (C, D) MS of TMT-labelled WCL from DLD1 cells. Raw peptide abundances from independent runs were normalized and scaled. The mean value of each identified protein was then converted to log2FC and presented as a waterfall plot. (E) Differential expression of proteins that are enriched from the “postreplication repair” pathway. (F) Heatmap of downregulated transcripts used to identify secondary clusters in the STRING PPI network. (G) Oxidative stress was assessed by staining live DLD1 cells with MitoSOX and analyzing the indicated samples via flow cytometry (n = 3). Treatment with 100 pM H2O2 for six hours was used as a positive control (n = 3). Data are presented as mean ± SEM. p-values < 0.05 were considered significant.

[0017] Figure 10: Phenotypic profiling of replication stress. (A)1H NMR structural information of NYH002-alkyne probe (NYH002P). (B, C) Synchronous cell cycle profile of propidium iodide-stained DLD1 cells at 16 hours with 10 pM APH to achieve Gi / S-phase arrest or the use of 10 pM RO-3306 to arrest cells at G2-phase. Upon release (one and six hours), APH-treated cells entered S-phase, while RO-3306-treated cells entered Gi-phase. (D, E) Representative - H2AX immunofluorescence images of G1 / S- or G2-phase synchronized DLD1 cells treated with 1 pM NYH002, as indicated by the different time points. Dash boxes inform recruitment of - H2AX foci (arrows, white) to the site of DNA DSB. Scale bar: 10 pm. (F) DNA fibers presented as immunofluorescence images of pulse-labelled DLD1 cells with CldU and IdU, treated with either DMSO or 1 pM NYH002 for 30 mins. Scale bar: 20 pm. (G) Fluorescence intensity of NYH200P-AF647 fluorophore and R-loop (arrows, white) as revealed by S9.6 staining at six hours post-treatment. Scale bar: 5 pm. (H) Quantification of ssDNA foci per cell. DLD1 cells were pulse-labelled with 10 pM IdU for 24 hours, followed by treatment with 1 pM NYH002 for an additional 24 hours. DNA was processed under native conditions to detect ssDNA. (I) Representative images of yH2AX-positive cells as a readout for replication-induced DSBs. DLD1 cells were transfected with either empty vector (EV) or RNaseHI plasmid for 24 hours, followed by treatment with 1 pM NYH002. Scale bar: 5 pm. Data are presented as mean ± SEM. Mann-Whitney U test (H). p-values < 0.05 were considered significant.

[0018] Figure 11: NYH002 probe identifies ILF2-DHX9 axis. (A) Representative immunofluorescence images of competitive binding between NYH002 and NYH002P-AF647fluorescent probe (arrow, yellow) in the nucleus of DLD1 cells. Scale bar: 10 pm. (B, C) A representative silver-stained gel of NYH002P co-immunoprecipitation with WCL of DLD1 cells. The red dash box indicates direct (core) drug-protein interactions, while the yellow dash boxes indicate indirect (associated) drug-protein interactors. All gel bands (B1-B4) were processed for label-free quantification and protein identification to match the corresponding molecular weight of the excised region. (D) Interrogation of the CORUM database revealed that 154 out of 8,845 nuclear complexes contained at least one NYH002P-associated protein. (E) Immunoblot of indirect candidate proteins through NYH002P immunoprecipitation with WCL of DLD1 cells. Proteins of interest were randomly selected from each functional group as shown. Input represents 1% of the total WCL. (F) AlphaFold3 prediction of an in silica ILF2 complex. (G) Determination of direct drug-protein interactions was based on the total number of PLA foci observed between NYH002P and the identified proteins of the ILF2 complex. A Pearson correlation coefficient greater than 0.7 indicates a high frequency of protein recruitment and activity (n = 3). (H) Negative control for PLA between DMSO and the various proteins of the ILF2 complex. (I) Representative image of PLA showing the interaction between ILF2 and DHX9 in DLD1 cells. Scale bar: 10 pm. (J) Immunoprecipitation of ILF2 to detect DHX9 in WCL from DLD1 cells (n = 3). (K) Co-immunoprecipitation of DHX9 to detect R-loop-associated helicases in WCL from DLD1 cells.(L) Quantification of PLA foci comparing ILF2-WRN interactions to DHX9-WRN interactions (n = 3). (M) Quantification of PLA foci comparing ILF2-SETX interactions to DHX9-SETX interactions (n = 3). Data are presented as mean ± SEM. Mann-Whitney U test (L and M). p-values < 0.05 were considered significant.

[0019] Figure 12: Identification of Gi / S checkpoint deficient cancer cells. (A) HR proficiency was determined by the induction and resolution of BRCA1 -positive cells (> 5 foci per nucleus) following 2 Gy ionizing radiation (IR) in DLD1 cells. (B) A simplified Gi / S cell-cycle concept map. (C) Gene expression correlation matrix for Gi-, Gi / S-, and S-phase cell cycle-related genes from the TCGA pancancer cohort. The size of the circle denotes significance, while the numerical readout informs the correlation value between genes. (D) Principal component analysis plot of Gi / S gene candidates with high correlation was based on the gene expression of the TCGA pan-cancer cohort. CCND1 gene expression was used as a negative control. (E) Kaplan-Meier (KM) plot of high and low expression levels of CCNE1, E2F1, E2F2, and CDC25A. Gene significance was ranked based on the greatest difference in 50% overall survival. (F) RB1-mutant pan-cancer patients (%) from TCGA exhibit differences in CCNE2 and E2F1 gene expression. (G) Selection of cancer cell lines with differential CCNE1 and E2F1 expressions (high vs low) was performed by Z-scoring cell lines from the Cancer Cell Line Encyclopedia (CCLE) database. A pair-matched cell line, MCF7 and MDA-MB-436, was selected to represent breast cancer, whereas a non-paired tumor comprising U251 and U2OS represents glioblastoma and osteosarcoma, respectively. (H) Representative immunofluorescence images of S9.6 staining in cancer cells treated with either DMSO or 1 pM NYH002 for 24 hours. Scale bar: 10 pm. Data are presented as mean ± SEM. Unpaired two-tailed t-test (A) and Mantel-Cox test (E). p-values < 0.05 were considered significant, whereas N.S was regarded as not significant.

[0020] Figure 13: Identification of HR proficient and deficient cell lines. (A, B, C, D) Comparison of pan-cancer patients from TCGA exhibiting high or low expression of Gi / S-phase genes, CCNE2 andE2F1, in association with mutations in DDR genes. Expression of Gi-phase genes, CCND1 and CDK4, was used as a negative control to assess cell cycle phase specificity. (E, F) Gene expression of CCNE1 in normal and tumor samples from the TCGA cohort (left), including corresponding patients (right) with mutations in 70 out of 101 DDR genes. (G, H) Gene expression of E2F1 in normal and tumor samples from the TCGA cohort (left), including corresponding patients (right) with mutations in 34 out of 101 DDR genes. (I) Venn diagram showing the overlap of mutated DDR genes (n = 31 ) in pan-cancer TCGA patients with high gene expression of CCNE1 and E2F1. (J, K) Mutated DDR genes associated with high expression of CCNE1 and E2F1, and their involvement in various DNA DSB repair pathways, including pathway enrichment analysis using STRING. (L) Z-score ranking of the DDR library (n = 239) that is based on the synergistic efficacy of individual siRNA genes and NYH002 treatment. (M) An overall view of genomic scar score (loss of heterozygosity, LOH; telomeric allelic imbalance, TAI; large-scale transitions, LST) in different solid cancers from the TCGA cohort for HRD characterization. (N) Ranking of HRD scores in the CCLE database and the selection of pan-cancer cell lines classified as either HR-proficient (< 42 score) or HRD (> 42 score). (O) Top eight most frequent number of HRD solid cancer cell lines in the CCLE database. (P) Selection of HR-proficient and HRD pair-tumor cell lines was based on the genomic scar score (LOH, TAI, LST). (Q) NYH002 dose-response curve of HR-proficient MDA-MB-231 and HRD MDA-MB-436 after seven days of treatment (n = 3). (R) In vivo dose escalation in non-tumorigenic animals that received intraperitoneal injections on alternate days. Animal behaviour and weight were assessed to evaluate drug toxicity. (S, T) In vivo therapeutic efficacy of NYH002 was assessed in HR-proficient and HRD tumor models for both lung and breast cancer. Individual tumor weights were recorded at the endpoint following a controlled cull. Data are presented as mean ± SEM. Unpaired two-tailed t-test (A, B, C, D, E, G, S, and T). p-values < 0.05 were considered significant whereas N.S was regarded as not significant.DETAILED DESCRIPTION OF INVENTION

[0021] Exemplary, non-limiting examples of the present disclosure will now be described.

[0022] The present disclosure addresses the need for improved methods for treating cancer, particularly in subjects having cancers characterized by defects in DNA damage response pathways, in particular homologous recombination deficiency.

[0023] In one aspect, there is provided a method of treating a DNA damage response deficient cancer in a subject, the method comprising administering an effective amount of a compound of formula I, or a pharmaceutically acceptable salt or solvate thereof, to the subject,Q Me■i OR2MeR Owhere R1and R2each independently represent H, -C(O)R3or -C(O)Ci-e alkyl, which latter group is unsubstituted or substituted by one or more groups selected from halo and R4, or R1represents -C(O)R3or -C(O)Ci-e alkyl, which latter group is unsubstituted or substituted by one or more groups selected from halo and R4, and R2represents -C(O)C(=CH2)CH3;R3, when present, represents aryl, cycloalkyl ora heterocyclic ring system, where each of aryl, cycloalkyl and the heterocyclic ring system is unsubstituted or substituted by one or more groups selected from halo, Ci-3 alkyl, and NO2, where C1-3 alkyl is unsubstituted or substituted by one or more halo groups; R4, when present, represents aryl, cycloalkyl ora heterocyclic ring system, where each of aryl, cycloalkyl and the heterocyclic ring system is unsubstituted or substituted by one or more groups selected from halo and C1-3 alkyl, where C1-3 alkyl is unsubstituted or substituted by one or more halo groups.

[0024] R1may represent H, -C(O)R3or -C(O)Ci-e alkyl, which latter group is unsubstituted or substituted by one or more groups selected from halo and R4, or when R2represents -C(O)C(=CH2)CH3, R1may represent -C(O)R3or -C(O)Ci-e alkyl, which latter group is unsubstituted or substituted by one or more groups selected from halo and R4.

[0025] In other words, when R2represents -C(O)C(=CH2)CH3, then R1is not H.

[0026] In some examples, R1may represent -C(O)R3or-C(O)Ci-e alkyl, which latter group is unsubstituted or substituted by one or more groups selected from halo and R4.

[0027] In some examples, R2may represent -C(O)C(=CH2)CH3.

[0028] In some examples, R1and R2may each independently represent H, -C(O)R3or -C(O)Ci-3 alkyl, which latter group may be unsubstituted or substituted by one or more groups selected from halo and R4.

[0029] In some such examples, R1and R2may each independently represent -C(O)R3or -C(O)Ci-3 alkyl, which latter group may be unsubstituted or substituted by one or more groups selected from halo and R4.

[0030] In some examples, R1may represent -C(O)R3or -C(O)Ci-3 alkyl, which latter group may be unsubstituted or substituted by one or more groups selected from halo and R4, and R2may represent -C(O)C(=CH2)CH3.

[0031] In some such examples, R1may represent -C(O)R3or-C(O)Ci-3 alkyl, which latter group may be unsubstituted or substituted by one or more groups selected from halo and R4, and R2may represent -C(O)C(=CH2)CH3.

[0032] In some examples, R1may represent -C(O)R3and R2may represent -C(O)R3or -C(O)C(=CH2)CH3.

[0033] R3, when present, represents aryl, cycloalkyl or a heterocyclic ring system, where each of aryl, cycloalkyl and the heterocyclic ring system is unsubstituted or substituted by one or more groups selected from NC and, more particularly, halo and C1-3 alkyl, where C1-3 alkyl is unsubstituted or substituted by one or more halo groups.

[0034] In some examples, R3, when present, may represent aryl or a heterocyclic ring system, where each of aryl and the heterocyclic ring system may be unsubstituted or substituted by one or more groups selected from NO2 and, more particularly, halo and C1-3 alkyl, where the C1-3 alkyl may be unsubstituted or substituted by one or more halo groups.

[0035] In some examples, R3, when present, may be aryl that is unsubstituted or substituted by one or more groups selected from NO2 and, more particularly, halo and C1-3 alkyl, where C1-3 alkyl is unsubstituted or substituted by one or more halo groups.

[0036] In some examples, R3, when present, may be phenyl that may be unsubstituted or substituted by one or more groups selected from NO2 and, more particularly, F and Ci alkyl, where Ci alkyl may be unsubstituted or substituted by one or more halo groups.

[0037] In any of the above examples of the invention, the substituent present on R3may be substituted by a substituent that is not NO2. In other words, in any of the above examples of the invention R3may represent an aryl, cycloalkyl or a heterocyclic ring system (e.g. aryl or a heterocyclic ring system, such as aryl, for example phenyl), where each of aryl, cycloalkyl, the heterocyclic ring system and phenyl may be unsubstituted or substituted by one or more groups selected from halo (e.g. F) and C1-3 alkyl (e.g. Ci alkyl), where the C1-3 alkyl (or Ci alkyl) is unsubstituted or substituted by one or more halo (e.g. F) groups.

[0038] R4, when present, represents aryl, cycloalkyl or a heterocyclic ring system, where each of aryl, cycloalkyl and the heterocyclic ring system is unsubstituted or substituted by one or more groups selected from halo and C1-3 alkyl, where C1-3 alkyl is unsubstituted or substituted by one or more halo groups.

[0039] In some examples, R4, when present, may represent aryl or a heterocyclic ring system, where each of aryl and the heterocyclic ring system may be unsubstituted or substituted by one or more groups selected from halo and C1-3 alkyl, where the C1-3 alkyl may be unsubstituted or substituted by one or more halo groups. In some examples, R4, when present, may be aryl that is unsubstituted or substituted by one or more groups selected from halo and C1-3 alkyl, where C1-3 alkyl is unsubstituted or substituted by one or more halo groups.

[0040] In some examples, R4, when present, may be phenyl that may be unsubstituted or substituted by one or more groups selected from F and Ci alkyl, where Ci alkyl may be unsubstituted or substituted by one or more halo groups.

[0041] In some examples where R4is present, it may be present as a substituent on a methyl group. For example, the C1-6 alkyl moiety and R4may together represent a substituted or unsubstituted benzyl group, where the substituents are as defined above.

[0042] Where groups above are referred to as comprising “one or more” substituents, they may be substituted with one substituent or more than one substituent, for example, they may be substituted by one to six substituents, such as one to five substituents, e.g. one, two, or three substituents.

[0043] By way of example, when an alkyl group (e.g. a C1-3 alkyl group such as methyl) is substituted by one or more substituents (e.g. halo groups), said alkyl group may be substituted by one, two or three substituents (e.g. halo groups). The halo groups may be fluoro groups. An example of an alkyl group substituted with one or more halo (e.g. fluoro) groups is trifluoromethyl.

[0044] As a further example, when an aryl group (e.g. a phenyl group) is substituted by one or more substituents, the aryl group may be substituted by one to five substituents (e.g. halo groups or C1-3 alkyl groups, which C1-3 alkyl groups may themselves be substituted or unsubstituted as defined above). The aryl group may be a phenyl group. The halo groups may be fluoro groups. The C1-3 alkyl groups may be as defined above. An example of an aryl group (e.g. phenyl group) substituted with one or more halo (e.g. fluoro) groups is pentafluorophenyl.

[0045] In some specific examples, the compound of formula I is the following:

[0046] In some more specific examples, the compound of formula I is

[0047] The term “pharmaceutically acceptable salts” as used herein includes both pharmaceutically acceptable acid addition salts and pharmaceutically acceptable cationic salts. Such salts may be derived from mineral acids, organic acids, or metal cations. Suitable mineral acids include hydrochloric acid, hydrobromic acid, phosphoric acid, metaphosphoric acid, nitric acid, and sulphuric acid. Suitable organic acids include, for example, tartaric acid, acetic acid, citric acid, malic acid, lactic acid, fumaric acid, benzoic acid, glycolic acid, gluconic acid (e.g., D-gluconic), succinic acid, and arylsulphonic acids such as benzenesulphonic acid and p-toluenesulphonic acid. Salts may also be formed with metals such as sodium, magnesium, or preferably, potassium and calcium.

[0048] Suitable solvates of the compound of formula I include those formed by the incorporation of molecules of a non-toxic, pharmaceutically acceptable solvent (hereinafter referred to as the solvating solvent) into the solid-state structure (e.g., crystal structure) of the compound of formula I. Examples of suitable solvating solvents include water, alcohols such as ethanol, isopropanol, and butanol, as well as dimethylsulphoxide. The solvates may be stoichiometric or non-stoichiometric, and particularly preferred solvates are hydrates. Examples of hydrates include hemihydrates, monohydrates, and di hydrates.

[0049] As used herein, a “DNA damage response deficient cancer” refers to a cancer in which one or more pathways involved in detecting, signalling, repairing, or tolerating DNA damage are defective, impaired, dysregulated, or otherwise functionally deficient. The present disclosure is based, at least in part, on the finding that compounds of Formula I exhibit enhanced anti-cancer activity in cancers characterized by such defects.

[0050] The DNA damage response, or DDR, may include pathways involved in the response to DNA double-strand breaks and other forms of genotoxic stress, including, for example, homologous recombination, non-homologous end joining, Fanconi anemia pathway, microhomology-mediated end joining, single-strand annealing, DNA damage checkpoint signalling, DNA repair complex function, and related DNA repair pathways or networks. In some examples, a DNA damage response deficient cancer is a cancer having a defect in one or more genes involved in any of the foregoing pathways. In some examples, defects in one or more of these pathways render the cancer more susceptible to treatment with a compound of Formula I.

[0051] In some examples, the DNA damage response deficient cancer is characterized by a defect in one or more genes associated with DNA damage response or DNA repair. Such defect may comprise, for example, mutation, deletion, insertion, rearrangement, copy number loss, reduced expression, reduced protein level, reduced enzymatic activity, reduced pathway activity, loss of function, partial loss of function, or epigenetic silencing of a relevant gene. In some examples, the defect is determined functionally by a deficient DNA repair phenotype rather than by identification of a specific underlying mutation.

[0052] In some examples, whether a cancer is deficient in a DNA damage response pathway, deficient in a particular DNA repair factor, or characterized by elevated expression of one or more response-associated biomarkers may be determined by analysis of genomic DNA, RNA, protein, cellular phenotype, or a combination thereof. In some examples, such analysis comprises determining the presence of a mutation, deletion, insertion, rearrangement, or copy number loss in a relevant gene. In some examples, such analysis comprises determining reduced gene expression, reduced protein level, reduced pathway activity, or reduced cellular function associated with the relevant gene or pathway. In some examples, nucleic acid-based analysis comprises RT-qPCR, RNA sequencing, or genomic sequence analysis. In some examples, protein-based analysis comprises immunoblotting or immunofluorescence-based detection. In some examples, the cancer is classified by comparison with a matched normal sample, a control sample, a reference cohort, or a predetermined threshold value.

[0053] In some examples, the deficiency, biomarker status, or other cancer characteristic described herein is identified prior to treatment with a compound of Formula I. In some examples, such identification is performed using analysis of genomic DNA, RNA, protein, cellular phenotype, or a combination thereof. In some examples, the subject is selected for treatment with a compound of Formula I on the basis of such identified deficiency, biomarker status, or characteristic.

[0054] In some examples, identification prior to treatment comprises analysis of a tumor sample, a biopsy sample, a surgical specimen, a blood sample, a plasma sample, circulating tumor DNA, circulating tumor cells, or another biological sample obtained from the subject. In some examples, the identified deficiency or characteristic is determined by genomic analysis, transcript analysis, protein analysis, immunohistochemistry, immunoblotting, RT-qPCR, RNA sequencing, functional DNA repair assay, homologous recombination deficiency scoring, or a combination thereof.

[0055] In some examples, the DNA damage response deficient cancer is characterized by a defect in one or more genes selected from APTX, ATRIP, BARD1 , BLM, CHK1 , CHK2, DMC1, ETAA1 , FBH1 , LIG1 , LIG4, NBN, PALB2, PARP1 , PARP2, POLD1 , POLD2, RAD18, PRAD51D, RMI1, RPA1 , RPA2, RTEL1 , SETMAR, SHLD2, SLX4, SPIDR, TDP1 , UIMC1 , XRCC4, XRCC6, ATR, P16, P21 , E2F1 , E2F2, RB1 , PTEN, MRE11 , RAD50, and RAD51 .

[0056] In some examples, the DNA damage response deficient cancer is a homologous recombination deficient cancer. As used herein, “homologous recombination deficient” or “HR deficient” refers to a cancer that exhibits a deficiency in homologous recombination repair, whether due to mutation, loss, reduced function, or other impairment of one or more homologous recombination related genes or by virtue of a genomic instability profile consistent with homologous recombination deficiency. In some examples, the homologous recombination deficient cancer is distinguished from a homologousrecombination proficient cancer based on one or more homologous recombination deficiency associated parameters.

[0057] In some examples, the DNA damage response deficient cancer is identified on the basis of a homologous recombination deficiency score. In some examples, the score is determined using one or more measures of genomic instability, including loss of heterozygosity (LOH), telomeric allelic imbalance (TAI), large-scale state transitions (LST), or combinations thereof. In some examples, the homologous recombination deficiency score used to identify a DNA damage response deficient cancer may be compared with a threshold value selected according to the assay, scoring method, reference dataset, or clinical context. In some examples, the threshold value is at least about 30, at least about 35, at least about 40, at least about 42, at least about 45, or at least about 50. In some examples, the threshold value is about 42. In some examples, the threshold value is from about 35 to about 50, from about 40 to about 45, or from about 40 to about 42. In some examples, the threshold value is about 42.

[0058] In some examples, HR proficiency or deficiency is determined functionally. In some examples, the functional assay comprises inducing DNA damage, for example by ionizing radiation.

[0059] In some examples, the DNA damage response deficient cancer is a Gi / S checkpoint deficient cancer. As used herein, a “Gi / S checkpoint deficient cancer” refers to a cancer in which regulation of progression through the Gi phase and entry into S phase is defective, impaired, dysregulated, or otherwise functionally deficient. In some examples, such deficiency is associated with dysregulation of one or more components of the Gi / S regulatory network, including the RB / E2F pathway, Cyclin D / CDK4 / CDK6 signalling, Cyclin E / CDK2 signalling, CDC25A activity, Gi-S transcription, or combinations thereof. In some examples, a Gi / S checkpoint deficient cancer exhibits increased baseline replication stress, unresolved DNA damage, impaired resolution of replication stress-induced DNA double-strand breaks, or a combination thereof, thereby placing such cancer within the broader class of DNA damage response deficient cancers.

[0060] In some examples, the Gi / S checkpoint deficient cancer is characterized by increased or aberrant activity of one or more markers selected from Cyclin E (in particular CCNE1), E2F1 , E2F2, CDC25A, CCND1 , CDK4, and CDK6. In some examples, the Gi / S checkpoint deficient cancer is characterized by elevated CCNE1 expression, elevated E2F1 expression, elevated E2F2 expression, elevated CDC25A expression, elevated CCND1 expression, elevated CDK4 expression, elevated CDK6 expression, or any combination thereof. In some examples, elevated expression of one or more such markers is determined at the RNA level, for example by RT-qPCR or RNA sequencing, or at the protein level, for example by immunoblotting. In some examples, the elevation or reduction is relative to a normal sample, a control sample, a reference cohort, or a predetermined threshold.

[0061] In some examples, the DNA damage response deficient cancer is a homologous recombination proficient cancer characterized by deficiency in one or more of EXO1 , MSH3, and FEN1. As used herein, a “homologous recombination proficient cancer” or “HR proficient cancer” refers to a cancer that does not exhibit homologous recombination deficiency according to the criteria used to identify an HR deficient cancer, for example based on homologous recombination deficiency score, genomic instability profile, or another homologous recombination deficiency-associated parameter. In some examples, although such a cancer is HR proficient, it may nevertheless exhibit increased responsiveness totreatment with a compound of Formula I by virtue of deficiency in one or more additional DNA repair factors.

[0062] In some examples, the HR proficient cancer is characterized by deficiency in one or more of EXO1 , MSH3, and FEN1. In some examples, the deficiency comprises loss or reduction of function of EXO1 , MSH3, or FEN1. In some examples, the deficiency comprises reduced expression, reduced protein level, reduced activity, deletion, inactivating mutation, partial loss of function, or gene silencing of EXO1 , MSH3, or FEN1 . In some examples, deficiency in one or more of EXO1 , MSH3, and FEN1 is associated with increased sensitivity, enhanced responsiveness, or synthetic lethal interaction with treatment using a compound of Formula I.

[0063] In some examples, the HR proficient cancer is characterized by EXO1 deficiency. In some examples, the HR proficient cancer is characterized by MSH3 deficiency. In some examples, the HR proficient cancer is characterized by FEN1 deficiency. In some examples, the HR proficient cancer is characterized by deficiency in at least two of EXO1 , MSH3, and FEN1. In some examples, the HR proficient cancer is characterized by deficiency in each of EXO1 , MSH3, and FEN1.

[0064] In some examples, the cancer is a solid tumor. As used herein, a “solid tumor” refers to a non-hematological tumor forming a mass in an organ or tissue.

[0065] In some examples, treatment with a compound of Formula I provides potent anti-cancer activity. In some examples, such treatment reduces cancer cell survival, induces apoptosis, and increases markers of DNA damage in cancer cells. In some examples, treatment is associated with increased cleaved PARP, cleaved caspase-3, cleaved caspase-7, increased yH2AX foci, increased 53BP1 foci, and perturbation of cell-cycle distribution. In some examples, such activity reflects induction of transcription-replication conflict and DNA damage in cancer cells.

[0066] In some examples, treatment with a compound of Formula I provides broad anti-cancer activity across multiple solid tumor types. In some examples, the cancer is selected from the group consisting of lung cancer, breast cancer, stomach cancer, ovarian cancer, liver cancer, colorectal cancer, brain cancer, pancreatic cancer, prostate cancer, and bone cancer. In some examples, the cancer is lung cancer. In some examples, the cancer is breast cancer.

[0067] In some examples, the method further comprises administering one or more additional anticancer agent. In some examples, the one or more additional anticancer agent is administered together with, separately from, before, after, or sequentially with a compound of Formula I. In some examples, the one or more additional anticancer agent is selected to provide additive or synergistic anti-cancer activity. In some examples, the one or more additional anticancer agent is a DNA-damaging agent, a chemotherapeutic agent, a targeted therapeutic agent, an immunotherapeutic agent, a hormonal therapeutic agent, a radiotherapeutic agent, or a combination thereof.

[0068] In some examples, the one or more additional anticancer agent is a DNA-damaging agent. As used herein, a “DNA-damaging agent” refers to an agent that causes, directly or indirectly, DNA lesions, genotoxic stress, replication stress, impairment of DNA synthesis, or activation of DNA damage response pathways in cancer cells. In some examples, the DNA-damaging agent induces one or more forms of DNA damage selected from base damage, alkylation damage, crosslinking damage, strandbreak-associated damage, replication-associated damage, or combinations thereof. In some examples, the DNA-damaging agent is selected from temozolomide, methyl methanesulfonate, and 5-fluorouracil.

[0069] In some examples, the DNA-damaging agent is an alkylating agent. As used herein, an “alkylating agent” refers to an agent that introduces an alkyl group into a biological molecule, including DNA, thereby causing DNA damage and interfering with DNA replication, transcription, repair, or cell survival.

[0070] In some examples, administration of the compound of Formula I together with such additional anticancer agent results in increased anti-cancer activity or a synergistic effect. In some examples, the synergistic effect comprises greater inhibition of cancer cell growth, greater reduction in cell viability, or greater anti-cancer efficacy than administration of either agent alone.

[0071] In some examples, the subject has not previously received first-line anti-cancer therapy. In some examples, the subject is treatment-naive with respect to anti-cancer therapy. In some examples, the cancer is present in a subject who has not previously undergone a first-line anti-cancer treatment regimen for the cancer to be treated. In some examples, treatment with a compound of Formula I is administered as an initial anti-cancer treatment to such subject.

[0072] In some other examples, the subject has previously received first-line anti-cancer therapy. In some examples, the subject has undergone a first-line anti-cancer treatment regimen for the cancer to be treated. In some examples, the cancer is present in a subject who has previously been treated with first-line anti-cancer therapy. In some examples, treatment with a compound of Formula I is administered to such subject following receipt of first-line anti-cancer therapy.

[0073] The term “effective amount” refers to an amount of a compound, which confers a therapeutic effect on the treated subject (e.g. sufficient to treat or prevent the disease). The effect may be objective (i.e. measurable by some test or marker) or subjective (i.e. the subject gives an indication of or feels an effect). In some examples, the amount is selected according to the cancer type, route of administration, formulation, treatment schedule, combination regimen, and condition of the subject. In some examples, the amount is selected to achieve anti-cancer activity while maintaining an acceptable tolerability profile. In some examples, the effective amount may be determined in view of one or more pharmacodynamic, pharmacokinetic, safety, or efficacy parameters.

[0074] In some examples, the amount of the compound of Formula I is selected with reference to concentrations shown to have anti-cancer activity in cell-based assays. In some examples, the compound is used at a concentration of about 0.015 pM, about 0.1 pM, about 0.15 pM, about 1.0 pM, about 1.5 pM, or about 15 pM. In some examples, the compound is used at a concentration from about 0.01 pM to about 20 pM, from about 0.01 pM to about 5 pM, from about 0.05 pM to about 2 pM, or from about 0.1 pM to about 1.5 pM. In some examples, the compound is used at about 0.1 pM or about 1 .0 pM.

[0075] In some examples, the amount of the compound of Formula I is selected with reference to doses shown to have anti-tumor activity in animal models. In some examples, the compound is administered at a dose of about 25 mg / kg. In some examples, the dose is from about 1 mg / kg to about 100 mg / kg, from about 5 mg / kg to about 50 mg / kg, from about 10 mg / kg to about 40 mg / kg, or from about 20 mg / kg to about 30 mg / kg. In some examples, the dose is about 25 mg / kg.

[0076] In some examples, the compound of Formula I is administered once daily, once every two days, two or more times per week, or according to another intermittent schedule. In some examples, treatment is continued for a period of at least about 1 week, at least about 2 weeks, at least about 3 weeks, or at least about 4 weeks. In some examples, treatment is administered for about 2 weeks. In some examples, the dose and schedule are selected in view of the pharmacokinetic profile of the compound.

[0077] In some examples, the dose is selected to provide anti-cancer activity with acceptable tolerability. In some examples, tolerability is assessed with reference to one or more parameters selected from body weight change, hematological parameters, white blood cell count, and histological evaluation of one or more organs. In some examples, the dose is selected such that anti-tumor activity is achieved without a statistically significant adverse effect on white blood cell count. In some examples, tolerability is assessed by histological evaluation of liver and kidney tissue.

[0078] In some examples, when the compound of Formula I is administered together with one or more additional anticancer agent, the dose of the compound of Formula I and / or the additional anticancer agent may be adjusted relative to the dose used in monotherapy. In some examples, the compound of Formula I is administered at a dose or concentration sufficient to provide increased anti-cancer activity or a synergistic effect when used in combination with a DNA-damaging agent.

[0079] In some examples, the one or more additional anticancer agent is temozolomide. In some examples, temozolomide is administered at a dose of about 25 mg / kg. In some examples, temozolomide is administered in combination with the compound of Formula I administered at a dose of about 10 mg / kg. In some examples, administration of temozolomide together with the compound of Formula I results in increased anti-cancer activity or a synergistic effect, including greater suppression of tumor growth than would be achieved by either agent alone.

[0080] In some examples, the one or more additional anticancer agent is methyl methanesulfonate or 5-fluorouracil. In some examples, methyl methanesulfonate or 5-fluorouracil is administered in an amount effective to increase anti-cancer activity in combination with a compound of Formula I. In some examples, the amount of methyl methanesulfonate or 5-fluorouracil is selected to provide increased DNA damage signalling, increased apoptosis, increased inhibition of cancer cell growth, or a synergistic effect when used together with the compound of Formula I.

[0081] For the avoidance of doubt, in the context of the present invention, the term “treatment” includes references to therapeutic or palliative treatment of subjects in need of such treatment.

[0082] As used herein, the term "subject" refers to a mammal, including dog, cat, rat, mouse, monkey, cow, horse, goat, sheep, pig, camel, and, most preferably, a human. The term does not denote a particular age or sex. Thus, adult and newborn subjects, whether male or female, are intended to be covered.

[0083] The compounds as disclosed herein may be administered by any suitable route, but may particularly be administered orally, intravenously, intramuscularly, cutaneously, subcutaneously, transmucosally (e.g. sublingually or buccally), rectally, transdermally, nasally, pulmonarily (e.g. tracheally or bronchially), topically, by any other parenteral route, in the form of a pharmaceutical preparation comprising the compound in a pharmaceutically acceptable dosage form. Particular modesof administration that may be mentioned include oral, intravenous, cutaneous, subcutaneous, nasal, intramuscular or intraperitoneal administration.

[0084] Compounds of formula I will generally be administered as a pharmaceutical formulation in admixture with a pharmaceutically acceptable adjuvant, diluent or carrier, which may be selected with due regard to the intended route of administration and standard pharmaceutical practice. Such pharmaceutically acceptable carriers may be chemically inert to the active compounds and may have no detrimental side effects or toxicity under the conditions of use. Suitable pharmaceutical formulations may be found in, for example, Remington, The Science and Practice of Pharmacy, 19th ed., Mack Printing Company, Easton, Pennsylvania (1995). For parenteral administration, a parenterally acceptable aqueous solution may be employed, which is pyrogen free and has requisite pH, isotonicity, and stability. Suitable solutions will be well known to the skilled person, with numerous methods being described in the literature. A brief review of methods of drug delivery may also be found in e.g. Langer, Science (1990) 249, 1527.

[0085] Otherwise, the preparation of suitable formulations may be achieved routinely by the skilled person using routine techniques and / or in accordance with standard and / or accepted pharmaceutical practice.

[0086] The amount of compound of formula I in any pharmaceutical formulation used in accordance with the present invention will depend on various factors, such as the severity of the condition to be treated, the particular patient to be treated, as well as the compound(s) which is / are employed. In any event, the amount of compound of formula I in the formulation may be determined routinely by the skilled person.

[0087] For example, a solid oral composition such as a tablet or capsule may contain from 1 to 99 % (w / w) active ingredient; from 0 to 99% (w / w) diluent or filler; from 0 to 20% (w / w) of a disintegrant; from 0 to 5% (w / w) of a lubricant; from 0 to 5% (w / w) of a flow aid; from 0 to 50% (w / w) of a granulating agent or binder; from 0 to 5% (w / w) of an antioxidant; and from 0 to 5% (w / w) of a pigment. A controlled release tablet may in addition contain from 0 to 90 % (w / w) of a release-controlling polymer.

[0088] A parenteral formulation (such as a solution or suspension for injection or a solution for infusion) may contain from 1 to 50 % (w / w) active ingredient; and from 50% (w / w) to 99% (w / w) of a liquid or semisolid carrier or vehicle (e.g. a solvent such as water); and 0-20% (w / w) of one or more other excipients such as buffering agents, antioxidants, suspension stabilisers, tonicity adjusting agents and preservatives.

[0089] Depending on the type of cancer, and the subject, to be treated, as well as the route of administration, compounds of formula I may be administered at varying therapeutically effective doses to a patient in need thereof.

[0090] However, the dose administered to a mammal, particularly a human, in the context of the present invention should be sufficient to effect a therapeutic response in the mammal over a reasonable timeframe. One skilled in the art will recognize that the selection of the exact dose and composition and the most appropriate delivery regimen will also be influenced by inter alia the pharmacological properties of the formulation, the nature and severity of the condition being treated, and the physical condition and mental acuity of the recipient, as well as the potency of the specific compound, the age,condition, body weight, sex and response of the patient to be treated, and the stage / severity of the disease.

[0091] Administration may be continuous or intermittent (e.g. by bolus injection). The dosage may also be determined by the timing and frequency of administration. In any event, the medical practitioner, or other skilled person, will be able to determine routinely the actual dosage, which will be most suitable for an individual patient. The above mentioned dosages are exemplary of the average case. There can, of course, be individual instances where higher or lower dosage ranges are merited, and such are within the scope of this invention.

[0092] In some examples, the present disclosure provides a method of treating cancer, including any cancer or cancer subtype described herein, in a subject in need thereof, comprising administering an effective amount of a compound of Formula I or a pharmaceutically acceptable salt, solvate, or pharmaceutical composition thereof. In some examples, the present disclosure provides a compound of Formula I, or a pharmaceutically acceptable salt, solvate, or pharmaceutical composition thereof, for use in treating cancer, including any cancer or cancer subtype described herein. In some examples, the present disclosure provides use of a compound of Formula I, ora pharmaceutically acceptable salt, solvate, or pharmaceutical composition thereof, in the manufacture of a medicament for treating cancer, including any cancer or cancer subtype described herein.

[0093] In some specific examples, the present disclosure provides a compound of formula I, or a pharmaceutically acceptable salt or solvate thereof, for use in the treatment of a DNA damage response deficient cancer in a subject, wherein R1and R2are defined herein. In some specific examples, the treatment of a DNA damage response deficient cancer further comprises one or more additional anticancer agent.

[0094] In some other specific examples, the present disclosure provides use of a compound of formula I, or a pharmaceutically acceptable salt or solvate thereof, in the manufacture of a medicament for treating a DNA damage response deficient cancer in a subject, wherein R1and R2are defined herein. In some specific examples, the compound of formula I, ora pharmaceutically acceptable salt or solvate thereof, is to be administered to the subject with one or more additional anticancer agent.

[0095] In some specific examples, the compound of formula I is selected from the group consisting of:

[0096] In some specific examples, the DNA damage response deficient cancer is a homologous recombination (HR) deficient cancer. In some specific examples, the HR deficient cancer has an HR deficiency score. In some specific examples, an HR deficiency score of at least 42 indicates a HR deficient cancer. In some specific examples, the DNA damage response deficient cancer is a Gi / S checkpoint deficient cancer. In some specific examples, the cancer exhibits elevated cyclin E expression and / or elevated E2F1 expression, optionally wherein the cyclin E is CCNE1. In some specific examples, the DNA damage response deficient cancer is a HR proficient cancer characterized by deficiency in one or more of EXO1 , MSH3, and FEN1. In some specific examples, the DNA damage response deficient cancer is characterized by a defect in one or more genes selected from the group consisting of APTX, ATRIP, BARD1 , BLM, CHK1 , CHK2, DMC1, ETAA1 , FBH1 , LIG1 , LIG4, NBN, PALB2, PARP1 , PARP2, POLD1 , POLD2, RAD18, PRAD51D, RMI1 , RPA1 , RPA2, RTEL1 , SETMAR, SHLD2, SLX4, SPIDR, TDP1 , UIMC1, XRCC4, XRCC6, ATR, P16, P21 , E2F1 , E2F2, RB1 , PTEN, MRE11 , RAD50, and RAD51 . In some specific examples, the cancer is a solid tumor. In some specificexamples, the cancer is selected from the group consisting of lung cancer, breast cancer, stomach cancer, ovarian cancer, liver cancer, colorectal cancer, brain cancer, pancreatic cancer, prostate cancer, and bone cancer. In some specific examples, the cancer is lung cancer or breast cancer.

[0097] In some specific examples, the additional anticancer agent is a DNA-damaging agent. In some specific examples, the additional anticancer agent is an alkylating agent. In some specific examples, the additional anticancer agent is selected from the group consisting of temozolomide, methyl methanesulfonate, and 5-fluorouracil. In some specific examples, the subject has not previously received first-line anti-cancer therapy. In some other specific examples, the subject has previously received first-line anti-cancer therapy.

[0098] The invention illustratively described herein may suitably be practiced in the absence of any element or elements, limitation or limitations, not specifically disclosed herein. Thus, for example, the terms “comprising”, “including”, “containing”, etc. shall be read expansively and without limitation. Additionally, the terms and expressions employed herein have been used as terms of description and not of limitation, and there is no intention in the use of such terms and expressions of excluding any equivalents of the features shown and described or portions thereof, but it is recognized that various modifications are possible within the scope of the invention claimed. Thus, it should be understood that although the present invention has been specifically disclosed by preferred embodiments and optional features, modification and variation of the inventions embodied therein herein disclosed may be resorted to by those skilled in the art, and that such modifications and variations are considered to be within the scope of this invention.

[0099] As used in this application, the singular form “a”, “an”, and “the” include plural references unless the context clearly dictates otherwise.

[0100] As used herein, the term “about”, in the context of concentrations of components of the formulations, typically means + / - 5% of the stated value, more typically + / - 4% of the stated value, more typically + / - 3% of the stated value, more typically, + / - 2% of the stated value, even more typically + / -1% of the stated value, and even more typically + / - 0.5% of the stated value.

[0101] As used herein, the percentage (%) can refer to “% (w / v)” (percent weight to volume), “% (v / v)” (percent volume to volume), or “% (w / w)” (percent weight to weight), unless specified otherwise.

[0102] Throughout this disclosure, certain embodiments may be disclosed in a range format. It should be understood that the description in range format is merely for convenience and brevity and should not be construed as an inflexible limitation on the scope of the disclosed ranges. Accordingly, the description of a range should be considered to have specifically disclosed all the possible sub-ranges as well as individual numerical values within that range. For example, description of a range such as from 1 to 6 should be considered to have specifically disclosed sub-ranges such as from 1 to 3, from 1 to 4, from 1 to 5, from 2 to 4, from 2 to 6, from 3 to 6 etc., as well as individual numbers within that range, for example, 1 , 2, 3, 4, 5, and 6. This applies regardless of the breadth of the range.

[0103] The invention has been described broadly and generically herein. Each of the narrower species and sub-generic groupings falling within the generic disclosure also form part of the invention. This includes the generic description of the invention with a proviso or negative limitation removing anysubject matter from the genus, regardless of whether or not the excised material is specifically recited herein.

[0104] Other embodiments are within the following claims and non- limiting examples. In addition, where features or aspects of the invention are described in terms of Markush groups, those skilled in the art will recognize that the invention is also thereby described in terms of any individual member or subgroup of members of the Markush group.EXAMPLES

[0105] Non-limiting examples of the invention and a comparative example will be further described in greater detail by reference to specific Examples, which should not be construed as in any way limiting the scope of the invention.

[0106] EXAMPLE 1. EXEMPLARY COMPOUNDSNameNYH001NYH101NYH002NYH003NYH004 n X ■n ~n. II4 ) . °V\JWT°" ’ \ e swt?T / nr 1 V g (“ J .v °'IV— n O 1 d F3< / < o=> s NYH005 ©MeO \CQ . ° / » Me h °°\ 'X\=o0_ / F^C / V

[0107] EXAMPLE 2. MATERIAL AND METHODS

[0108] Human and Animal Ethics

[0109] Patient recruitments were carried out in accordance with the approval of the Institutional Review Board of Nanyang Technological University (NTU). For animal studies, experiments were conducted in accordance with the recommendations of the National Advisory Committee for Laboratory Animal Research guidelines, under the Animal & Birds (Care and Use of Animals for Scientific Purposes) Rules of Singapore. The Institutional Animal Care and Use Committee of NTU approved the current protocol.

[0110] Observational Study

[0111] In a retrospective research initiative conducted offsite at NTU, patients who had previously undergone integrative medicine treatment were invited to participate in an observational study. Participant eligibility was assessed in accordance with the approved protocol. Evaluation was based on a review of participants' past medical histories, with a specific inclusion criterion stipulating a minimum six months of integrative medicine use. The integrative medicine regimen comprised a minimum daily oral administration of combined PAs, which were derived from medicinal plant materials. Additional criteria included the periodic conduct of questionnaires, and the collection of routine pathological reports of biomarkers and / or medical imaging conducted before and after the integrative medicine treatment. Informed consent was obtained from all patients. All biographical data were de-identified. Financial compensation was not offered for participation in this study.[QQ1121 Cell Culture

[0113] Unless otherwise stated, all cell lines were grown in culture medium supplemented with 10% fetal bovine serum (FBS) (Thermo Fisher Scientific) and 1% penicillin / streptomycin (Cytiva). DLD-1 , HCT116, H1299, Huh7, AGS, PC3, A2780, and A673, A549, HepG2, LnCAP cells were cultured in RPMI1640 Medium (Gibco). MDA-MB-231, MDA-MB-436, U2OS, and U251 were cultured in DMEM (Gibco). Capan-1 was cultured in IMDM (Gibco) supplemented with 20% FBS and 1%penicillin / streptomycin. BJ-5Ta was cultured in a 1 :1 ratio of DMEM and Medium 199, supplemented with 10% FBS, 1% penicillin / streptomycin, and 0.01 mg / ml hygromycin B (Nacalai Tesque). All cells were cultured in a humidified incubator at 37°C with 5% CO2, routinely screened for mycoplasma contamination, and authenticated by STR profile.

[0114] Phytotherapeutics

[0115] Medicinal plant materials, PA1 (Clinacanthus nutans), PA2 (Strobilanthes crispa L), PA3 (Elephantopus tomentosus L), PA4 (Leea indica), PA5 (Houttuynia cordata), and PA6 (Zebrina pendula Schnizl) were cleaned, cryodesiccated and grounded into a fine powder with a BioloMix grinder. To achieve bioactive extracts, the powdered materials were suspended in 60% aqueous ethanol at a ratio of 1 :30 (w / v) and subjected to continuous agitation at room temperature. Mixture was centrifuged, and the resulting supernatant was concentrated overnight at 37°C using a vacuum centrifuge (Concentrator Plus, Eppendorf, USA). The dry pellet was weighed and stored at 4°C. As a ready-to-use bioactive extract, the pellet was resuspended in sterile water.

[0116] Chemicals

[0117] APH, RO-3306, MMS and 5FU were purchased from Sigma-Aldrich. TMZ and 5,6-Dichloro-1-P-D-ribofuranosylbenzimidazole (DRB) were obtained from MedChem Express and Merck, respectively.

[0118] RNA Interference

[0119] The human ON-TARGETp / us DDR siRNA library (Dharmacon) was obtained as SMARTpool reagents, each comprising a mixture of four siRNAs targeting a single gene. In total, the library targeted 239 genes. Additional ON-TARGETp / us siRNA was also purchased for EX01, MSH3, FEN1 genes. siRNA negative control was obtained from Dharmacon.[001201 Plasmid

[0121] RNaseHI plasmid was a kind gift from Dr. Kah Suan Lim, National Cancer Centre, Singapore.

[0122] Public Datasets

[0123] Genomic, exon and RNA-seq datasets were obtained from TCGA.

[0124] Bioactive Compounds

[0125] PA3 crude powder (40 g) was sonicated in ethyl acetate and decanted repeatedly to achieve a greenish-yellow supernatant. The combined crude extracts were then filtered over Celite®, concentrated in vacuo, and purified by flash column chromatography (FCC) on silica gel (n-hexane / ethyl acetate, 4:1 to 1 :1). Purified material in ethyl acetate was treated with charcoal before passing through Celite®. The filtrate was concentrated under reduced pressure and further purified by gel permeation chromatography (LaboACE LC-5060, JAIGEL-2HR-40 column; 24 mg / ml; 10 ml injection; 30 ml / min flow rate), affording three fractions: Molephantinin and Molephantin, and a mixture of both compounds.

[0126] Molephantin Derivatives and Probe

[0127] NYH001 derivatives were synthesized for structure-activity relationships (SAR). Substituted benzoyl chlorides with various functional groups were added to a mixture of NYH001 , EtsN, and DMAP in anhydrous CH2CI2 at 0°C under argon. The reaction was performed at room temperature and concentrated in vacuo. The crude residue was further rinsed with saturated NaHCOs, extracted with dichloromethane, and the combined organic layers were filtered, purified, and further concentratedusing FCC on silica gel to produce solids of various derivatives. The structures and qualities of all compounds were examined using1H NMR,13C NMR, and MS (ESI).

[0128] Cell Divisions

[0129] Briefly, 2 x 10® viable single cells were pre-labelled with 10 pM CFSE (Thermo Fisher Scientific). Labelling was quenched with RPMI medium containing 10% FBS. A portion of these cells was fixed and stored at 4°C, while the remaining cells (5 x 105) were seeded in a T-25 flask with the appropriate treatment. After four days of culture, cells were harvested and rinsed twice with PBS prior to flow cytometric analysis. Cell proliferation data were analyzed using FlowJo software (BD Biosciences).

[0130] Cell Proliferation and Therapeutic Synergy

[0131] Cell viability was assessed using MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide]. Briefly, cells were seeded in 96-well plates at a density of 8 x 103to 1.2 x 104cells per well the day prior to experimentation. Following the indicated treatment, MTT was added to cells and incubated in the dark at 37°C. Formazan crystals were solubilized with DMSO. Absorbance was measured at 570 nm. Cell viability was calculated as a percentage relative to the untreated control. Half maximal effective concentration (ECso) values were calculated using GraphPad Prism. Alternatively, cell viability data were organized into a matrix format for analysis using SynergyFinder 3.0. The Highest Single Agent (HSA) model was selected for its conservative nature, minimizing false positives and reducing the risk of overestimating synergy between two drugs. For synthetic lethality, the coefficient of drug interaction (GDI) was calculated by dividing the observed cell viability of the combined treatment by the product of the cell viabilities for each individual treatment at the same concentration.

[0132] Colony Formation

[0133] Approximately 1 x 103cells were seeded into 6-well plates and allowed to attach for 48 hours. The cells were treated with 0.1 itM and 1 pM NYH002 for 1 hour at 37°C and incubated in fresh media for seven days to allow colony formation. The colonies were fixed in 4% paraformaldehyde (PFA) and stained with 0.5% crystal violet. Colonies were rinsed with water and air-dried, Images were taken with ChemiDoc MP Imaging System (Bio-Rad). The number and area of colonies were quantified using FIJI software.

[0134] Cell Cycle Profile

[0135] Approximately 6 x 105cells were seeded into 6-well plates and treated with NYH002 for 24 hours. Cells were harvested, fixed in -20°C 70% ethanol and stained with propidium iodide staining buffer (0.1% Triton-X, 40 mg / ml propidium iodide, 200 mg / ml RNase A). Samples were quantified with LSRFortessa™ (BD Biosciences) and analyzed in FlowJo™ software (BD Biosciences).

[0136] Immunofluorescence Stain

[0137] Cells were seeded onto coverslips in a 24-well plat and allowed to adhere overnight. Following treatment the next day, cells were fixed with 4% PFA and permeabilized with 0.2% Triton X-100 / PBS. For S9.6 staining, cells were fixed with ice-cold methanol. Primary antibodies were applied at room temperature, rinsed with TBS / 0.1% Tween, and replaced with Alexa Fluor-conjugated secondary antibodies. Nuclei were counterstained with DAPI (1 pg / ml), and coverslips were mounted in ProLong™ Gold Antifade Mountant (Thermo Fisher Scientific). The slides were imaged using a Zeiss Axio Observer.ZI fluorescence microscope or Zeiss LSM980 confocal microscope. Foci counts wereanalyzed per nucleus, with at least 100 nuclei per condition analyzed by Cel I Prof I le r. Manual verification was performed to exclude artifacts.

[0138] ssDNA Stain

[0139] Naive ssDNA labelling was performed as previously described. Briefly, cells were pulse-labelled with 10 itM IdU for 24 hours prior to treatment, washed with PBS, and pre-extracted with ice-cold CSK buffer (10 mM PIPES, 300 mM sucrose, 100 mM NaCI, 3 mM MgCl2, 0.2% Triton X-100) at room temperature. Cells were then fixed in 2% PFA, blocked in 10% BSA in PBS / 0.05% Tween and immunostained with anti-IdU primary antibody and Alexa Fluor 594-conjugated secondary antibody.

[0140] DNA Pulse-Labelled Fiber

[0141] DNA fiber assay was performed as previously described. Briefly, cells were pulse-labelled with 20 itM Cldu (Sigma-Aldrich) for 30 minutes at 37°C, treated with NYH002 for one hour before labelling with 100 pM IdU (Sigma-Aldrich) for 30 minutes. Cells were then lysed with spreading buffer (0.5% SDS, 200 mM Tris-HCI, 50 mM EDTA) and DNA fibers were stretched on the glass slide. Incorporated analogs were stained using rat anti-BrdU antibody (Abeam) and mouse anti-BrdU antibody (BD Biosciences). Images were acquired with a Zeiss Axio Observer.ZI fluorescence microscope and at least 200 fibers were quantified for each experiment.

[0142] Chromosome Spread

[0143] Treated cells were harvested and treated in hypotonic buffer (75 mM KCI) at 37°C. The buffer was removed by centrifugation and cells were fixed dropwise with ice-cold methanol / acetic acid (3:1). The cells were spun down at 200x g with the fixation step repeated twice before storing samples at4°C overnight. The cells were dropped onto glass slides and stained with DAPI (1 pg / ml). Images of the chromosome spread were acquired with Zeiss Axio ObserverZI fluorescence microscope.

[0144] Cell Transfection

[0145] Transfection of RNaseHI plasmid was performed using Lipofectamine 3000 (Thermo Fisher Scientific) while siRNAs were transfected into cells with DharmaFECTI (Dharmacon).

[0146] Proximity Ligation Assay

[0147] After the indicated treatments, cells cultured on coverslips were fixed with 4% formaldehyde and permeabilized with 0.2% Triton X-100 / PBS. PLA was performed using Naveni™ TriFlex Cell MR (Navinvi Diagnostics) according to the manufacturer’s instructions. Briefly, cells were immersed in blocking buffer at 37 °C, then incubated overnight at 4 °C with primary antibodies (1 :500) diluted in the supplied buffer. Cells were rinsed and incubated with secondary antibodies conjugated with either plus or minus PLA probes. This is followed by ligation and amplification steps. Cells were stained with DAPI before mounting on glass slides. PLA signal was detected using the Zeiss LSM980 confocal microscope under 40x objective lens. The images were analyzed and processed using Zen Blue software. The PLA signal and foci were quantified using the segmentation tool. Automated segmentation parameters were optimized to detect individual PLA foci. The total number of foci per nucleus was calculated, and at least 100 nuclei per condition was analyzed.

[0148] Cellular Thermal Shift Assay

[0149] CETSA was performed following the published protocol. Briefly, 1 x 107DLD-1 cells were resuspended in PBS supplemented with Halt™ Protease and Phosphatase Inhibitor Cocktail (ThermoFisher Scientific). Cells were subjected to freeze-thaw cycles, and lysate was centrifuged at 12,000x g. The supernatant was collected, aliquoted, and incubated with either DMSO or 100 itM NYH002 at room temperature on a rotator. Samples were subjected to a temperature gradient (40-60°C) by using a gradient thermal cycler (Eppendorf) and subsequently incubated at 25°C before placing on ice. Lysates were centrifuged at 16,000x g, and the supernatant was collected. Prior to SDS-PAGE, Laemmli buffer was added, and samples were denatured at 95°C.

[0150] Cell Lysis and Immunoprecipitation

[0151] Cell pellets were lysed in ice-cold RIPA or co-immunoprecipitation lysis buffer and centrifuged at 14,000x g to collect supernatants for immunoblotting and immunoprecipitation, respectively. For the latter, WCL were pre-cleared with Dynabeads™ M-280 streptavidin or protein A (Invitrogen) prior to protein estimation with Pierce BCA Kit (Thermo Fisher Scientific). Briefly, 10 pM of NYH002P was incubated with 1.5 mg of WCL overnight at 4°C, followed by click chemistry-mediated biotinylation and subsequent incubation with Dynabeads™ streptavidin. Alternatively, 1 pM of antibody was incubated with 1 mg of WCL overnight at 4°C and incubated with Dynabeads™ protein A. Samples were magnetically bounded and washed with lysis buffer and a high-salt (0.5 M NaCI) solution. Bound proteins were eluted with 2x Laemmli buffer (Bio-Rad) at 95°C.

[0152] SDS-PAGE, Silver Stain and Immunoblot

[0153] Denatured proteins were loaded onto an SDS-PAGE gel and electrophoresed. Silver staining was performed according to the manufacturer’s protocol (Pierce™ Silver Stain Kit). Alternatively, proteins were then transferred onto methanol-activated PVDF membranes using Trans-Blot® Turbo™ System (Bio-Rad). Membranes were blocked with 5% skimmed milk in 0.1% TBS / T prior to incubation with primary antibodies overnight at 4 °C. The following day, membranes were rinsed with 0.1 % TBS / T, followed by incubation with horseradish peroxidase (HRP)-conjugated secondary antibodies. Signal detection was performed using enhanced chemiluminescence reagents and visualized with the ChemiDoc MP Imaging System (Bio-Rad).

[0154] Nascent mRNA

[0155] Following the manufacturer's instructions, the nascent mRNA was stained using the Click-iT™ RNA Alexa Fluor™ 594 Imaging Kit (Thermo Fisher Scientific). Cells were seeded overnight at a density of 1.4 x 105per 12 mm glass coverslip. The following day, cells were treated with 1 pM NYH002P and incubated with 1 mM 5-ethynyl uridine (ED) in culture media for 1 hour to label nascent mRNA. EU-labelled cells were then fixed with 4% paraformaldehyde and permeabilized with 0.2% Triton X-100. Each coverslip was stained with Click-iT buffer following the recommended manual recipe. The staining buffer was rinsed off, cells were stained with 1 pg / ml DAPI and mounted with ProLong Diamond Antifade Mountant (Thermo Fisher Scientific).

[0156] Compound Probe-ClickiT

[0157] NYH002P was labelled and stained using the Click-iT™ EdU Cell Proliferation Kit for Imaging, Alexa Fluor™ 488 dye (Thermo Fisher Scientific) following manufacturer’s instructions. DLD-1 were seeded and treated with 1 pM NYH002P for six hours. Cells were fixed with 4% PFA and permeabilized with 0.2% Triton-X. Each coverslip was stained with freshly prepared buffer as instructed by the kit and were compatible for further staining with primary antibodies, DAPI, or for PLA experiments.

[0158] RT-qPCR

[0159] Total RNA was extracted using FastPure Cell / Tissue Total RNA Isolation Kit V2 (Cat# RC112-01 , Vazyme). Total RNA was reverse transcribed to cDNA using HiScript III All-in-one RT SuperMix Perfect for qPCR (Vazyme) on a gradient thermal cycler (Eppendorf). qPCR was performed with 500 nM forward and reverse primers (IDT) and Taq Pro Universal SYBR qPCR Master Mix (Vazyme) using Bio-Rad CFX96 Touch Real-Time PCR Detection System with CFX Manager software (Bio-Rad). HPRT was used as an internal control for normalization, and the relative expression level was calculated by the 2(-Delta Delta C(T)) method.

[0160] RNA Sequencing

[0161] The mRNA of treated samples was purified using poly-T oligo-attached magnetic beads and fragmented for cDNA synthesis. Directional and non-directional libraries were prepared with end repair, A-tailing, adapter ligation, size selection, amplification, and purification. Libraries were quantified and sequenced on an Illumina platform. Quality control included adapter trimming, removal of low-quality reads, and calculation of Q20, Q30, and GC content. Reads were mapped to the reference genome using Hisat2, and novel transcripts were assembled with StringTie. Gene expression levels were quantified using FeatureCounts and FPKM. Differential expression analysis was conducted with DESeq2 using the Benjamini-Hochberg method for multiple testing correction. Genes with an adjusted p-value < 0.05 and absolute fold-change > 2 were considered significantly differentially expressed.

[0162] Proteomics Sample Preparation and Analysis

[0163] For each condition, 100 pg of lysate was reduced, alkylated, and incubated overnight with Pierce trypsin protease MS grade (Thermo Fisher Scientific). Label-free or TMT 10-plex isobaric-tagged (Thermo Fisher Scientific) samples were first loaded onto an Xbridge™ C18 column where peptides were separated based on their hydrophobicity. The separated peptides were delivered through the Dionex EASY-Spray nano-electrospray to be ionized. These ions were introduced into a high-resolution Q Exactive orbitrap. A full MS scan (350-1 ,600 m / z range) was acquired at a resolution of 70,000 and a maximum ion accumulation time of 100 ms. Raw data files were processed and searched using Proteome Discoverer 2.1 (Thermo Fisher Scientific). SEQUEST was then used for protein identification. The normalization mode was based on the total peptide amount and a false discovery rate (FDR) for protein identification was < 1%. The protein list was further filtered with a minimum of 1 unique and 1 common peptide including matched molecular weight prior to pathway enrichment using KEGG, GO, Reactome and WikiPathway by Cytoscape. Alternatively, curated proteins were also performed using STRING and IntAct for PPI or the use of CORUM database to match protein complex.

[0164] Orthotopic and Xenograft Models

[0165] Briefly, tumor cells (1 x 106) in HBSS were injected subcutaneously into the flank or orthotopically into the mammary fat pad of nude mice. Tumors were allowed to grow till they reached a palpable size of approximately 100 mm3before randomizing into control and treated groups. NYH001 , NYH002 and NYH003 were dissolved in a vehicle solution consisting of 10% Kolliphor® EL, 10% DMSO, and 80% saline, therapeutics were administered via either the intraperitoneal or intratumoral route. Mice received treatment every other day for two weeks, unless stated otherwise. TMZ was dissolved in saline to a concentration of 10 mg / kg and administered orally once daily. Mice were weighed twice weekly,and tumor dimensions were regularly measured using calipers. Tumor masses were calculated as follows: T umor volume (mm3) = (length x width2) / 2. Mice were euthanized in a carbon dioxide chamber when tumor volume reached 1 ,800 mm3, weight loss exceeded 20%, or the treatment duration reached two weeks, whichever occurred first.

[0166] Cytotoxicity, Pharmacokinetics, and Biodistribution

[0167] For cytotoxicity assessment, J:NU / lnv mice received intraperitoneal injection of vehicle or 25 mg / kg NYH002 on alternate days for two weeks. After which, blood was collected by cardiac puncture and diluted in PBS containing 1 % FBS and 0.1 mM EDTA at a 1 :20 ratio, followed by filtration through a 0.45 pm cell strainer and collected in FACS tubes for flow cytometry assessment by cell size and granularity. For pharmacokinetics and biodistribution, BALB / cJ mice received a single intraperitoneal injection of either vehicle or 25 mg / kg NYH002. Blood was collected via cardiac puncture at indicated time points (0 - 24 hours) and transferred into vacutainer® EDTA tubes (BD). Organs were also harvested and homogenized in parallel. Both sample types were subsequently centrifuged. Serum from blood or supernatant from homogenized tissue was collected and individually mixed with ice-cold acetonitrile (ACN) at a 1 :3 ratio. Samples were precipitated at -20 °C overnight. The following day, samples were centrifuged at 4°C, and the supernatant was collected and concentrated. Resulting pellet was resuspended in 50% (w / v) ACN and analyzed by MS.

[0168] Histopathological staining

[0169] Tissues were fixed in 4% PFA, processed and embedded in paraffin, and subsequently sectioned at 5 pm thickness using a rotary microtome. Deparaffinized samples were stained with Mayer’s hematoxylin and Eosin Y, then dehydrated with ethanol. The slides were mounted with DPX Mountant for histology (Sigma) and imaged using Axio ObserverZI fluorescence microscope (Zeiss) under 20x objective lens.

[0170] Hi-C sequencing

[0171] Hi-C was performed using the Dovetail TopoLink V2 kit. Libraries were sent to NovogeneAIT for sequencing on Illumina NovaSeq at 300M PE150 reads per sample, with 2 biological replicates per condition. Fastq files from Illumina sequencing were first trimmed with trimmomatic [settings: ILLUMINACLIP: Adapters:2:30:10:8:true \ HEADCROP:5 \ SLIDINGWINDOW:4:10 \ LEADINGS \ TRAILING:3 \ MINLEN:30]. Reads were aligned on the hg19 genome using bwa default settings. Pairtools was used to prepare the paired interaction using the parse [settings: --min-mapq 10 -walks-policy 5unique -max-inter-align-gap 30], sort [settings: default], dedup [settings: --mark-dups] and split [settings: default] followed by samtools indexing and sorting of resulting .bam files and pairix indexing of resulting .pairs files. Finally, contact matrices were generated using cooler followed by cload [settings: pairix] and zoomify [settings: --balance] commands. Pile-ups were generated from .cool contact matrices using coolpup. py and its associated plotpup. py packages. The merge matrices from both replicates of each condition were used for this analysis, as it is not influenced by coverage biases. Hi-C heatmaps were generated from the .cool matrices using HiCExplorer. The two replicates with the closest coverage quality (U2 and H2 from the shared matrices), at 32 kb resolution, were used for imaging to alleviate coverage biases.

[0172] Data Analysis

[0173] All data presented were obtained from three independent experiments, unless otherwise specified. Significance was assessed using an unpaired, two-tailed Student’s t-test, assuming equal variance between the control and experimental groups, when the sample size was 10 or fewer. In the event of a larger sample size (>10), a normality distribution test was conducted using the Shapiro-Wilk Test and QQ-plot. For normally distributed data, a parametric test was used (unpaired two-tailed Student’s t-test or two-way ANOVA test). If the data is not normally distributed, the Mann-Whitney U test was employed. The significance of survival probability was calculated using the log-rank (Mantel-Cox) test. A p-value equal to or less than 0.05 was considered statistically significant in supporting the alternative hypothesis, unless stated otherwise.

[0174] EXAMPLE 3. RESULTS

[0175] Naturally Occurring Molephantin Displays High Therapeutic Potency and Cancer Selectivity

[0176] Harnessing cancer-specific toxicity for effective tumor eradication is a cornerstone of targeted therapy and serves as the underlying rationale for our retrospective observational study evaluating patient responses to integrative medicine involving orally administered phytotherapeutic agents (PAs). Of the 27 subjects evaluated, 20 were excluded due to ineligibility, withdrawal of consent, or non-compliance with the follow-up protocol (Figure 8A). Consequently, the cohort comprised three treatment-naive patients and four post-first-line treated patients, all of whom had completed a minimum of a six-month integrative medicine regimen, with progression-free survival and disease regression evaluated as the primary and secondary outcomes, respectively. Over the 1.5-year follow-up period, routine clinical evaluations documented therapeutic benefits in five patients, with no observed adverse events (Figure 8B-C and 1A). Notably, three treatment-naive patients exhibited a marked reduction in prostate-specific antigen (PSA) level and tumor size during the six-month treatment with the remaining patients demonstrating progression-free survival (Figure 1B-C).

[0177] Therapeutic activity based on the commonly administered PAs was subsequently evaluated in DLD1 cells where PA3 (Elephantopus tomentosus L.), demonstrated anti-proliferative properties (Figure 1D-1F). This series of assays indicated growth inhibition, prompting the isolation of bioactive compound(s) from the crude extract. Sequential fractionation by flash column chromatography and monitored by thin-layer chromatography (TLC), revealed presence of distinct compounds across the collected fractions. Fractions displaying similar TLC profiles were consolidated and further refined by gel permeation chromatography. Subsequent nuclear magnetic resonance (NMR) spectroscopy identified the high purity and structural integrity of Molephantin and Molephantinin (Figure 8D and 1G). Designated as NYH001 (Molephantin) and NYH101 (Molephantinin), these natural germacranolide sesquiterpenes compounds exhibited effective therapeutic activity within the micromolar range. Between the two bioactive compounds, NYH001 demonstrated greater potency as a small-molecule inhibitor (Figure 8E and 1H), leading to the evaluation of its cancer-specific toxicity using a panel of 10 solid cancer cell-lines. BJ-5TA, a non-cancerous fibroblast cell line, was also included as a control in the assessment of therapeutic efficacy. The latter exhibited the least sensitivity to NYH001 (ECso = 4.67 pM) as compared to the cancer cell line panel which responded within an ECso range of 0.82 pM to 4.22 pM (Figure 11). Furthermore, NYH001 treatment at 25 mg / kg in HCT116 tumor-bearing animal modeldemonstrated consistent therapeutic efficacy in mitigating tumor progression while exerting minimal systemic cytotoxicity (Figure 1 J-K).

[0178] NYH002 Suppresses Cancer Growth by Disrupting DNA Integrity

[0179] The isolated NYH001 molecule possesses a rare 10-membered macrocyclic backbone that includes an (E,Z)-dienone moiety spanning carbon atoms 1 to 4. Crucially, this ring structure is fused to a lactone ring known as an a-methylene-y-butyrolactone, and the molecule encompasses a cluster of four contiguous stereogenic centers at carbon atoms 5 to 8. This intricate chemical structure suggests the molecule may have unigue biological function, as demonstrated by its earlier observed ability to selectively induce cytotoxicity in solid cancer cell lines while sparing non-cancerous cells. To investigate the molecular mechanism of Molephantin, we employed a structure-activity relationship (SAR) approach, leveraging the chemical versatility of aromatic carboxylate scaffolds to first develop lead compounds. Five different derivatives, designated NYH002 - NYH006, were synthesized with structural variations to improve interactions with nucleophilic residues within the target protein, thereby enhancing therapeutic efficacy (Figure 9A-B and 2A). The design of our strategy enhances the drug-protein binding affinity while simultaneously reducing off-target interactions.

[0180] Treatment of a panel of 10 solid cancer cell lines (U251 , MB231 , A2780, H1299, HUH7, CAPAN1 , AGS, A673, DLD1 and PC3) with NYH002 - NYH006, revealed these compounds could achieve an ECso at nanomolar range (Figure 2B). All five derivatives exhibited improved efficacy with NYH002 having the greatest potency (Figure 2C). For a therapeutic safety evaluation, animals were daily administered with the top two lead candidates, NYH002 and NYH003 by intraperitoneal route for two weeks (Figure 2D). Not only did NYH002 show favorable tolerability in vivo, its therapeutic efficacy to elicit cancer cell death also exceeded that of the original NYH001 (Figure 2E).

[0181] We next utilized a system biology approach to determine the signalling network perturbed by NYH002. DLD1 cells received NYH002 treatment followed by tandem mass tag (TMT) labelling in conjunction with liquid chromatography-tandem mass spectrometry (LC-MS / MS) analysis. A total of 6,297 labelled proteins were then filtered for differentially expressed proteins of which 71 down-regulated proteins were determined (Figure 9C-D). Pathway enrichment analysis of this downregulated protein set indicated NYH002 as a disruptor of post-replication repair (Figure 9E and 2F). To substantiate this observation, transcriptome analysis was also conducted to complement the results of the pharmacoproteomics assessment (Figure 9F). Integration of both omics datasets supports a potential role for NYH002 in modulating the replication machinery (Figure 2G). This prompted the investigation into the integrity of DNA synthesis. Following 24 hours of NYH002 treatment, DLD1 cells exhibited G2 / M phase arrest, a critical checkpoint for resolving DNA strand breakages prior to cell division. Notably, NYH002-treated DLD1 cells exhibited gross chromosomal breaks resulting from unresolved DNA lesions (Figure 2H-I). Supporting this observation, we detected the presence of yH2AX and 53BP1 foci, which are well-established markers of DNA DSBs and are commonly recruited to sites of stalled replication forks. In NYH002-treated DLD1 cells, yH2AX and 53BP1 foci localized within intensely DAPI-stained nuclei (Figure 2J-K), suggesting a direct link to replication stress rather than oxidative stress-induced DNA damage (Figure 9G).

[0182] DNA Strand Breaks Arise from Collisions Between Transcription and Replication Machinery

[0183] Building on our observed evidence of DNA DSBs occurring in a cell cycle-dependent manner, we systematically investigated whether NYH002 induces replication stress. Pulse-chase imaging using our NYH002-alkyne (NYH002P) azide-activated fluorescent (AF594) revealed rapid nuclear localization of the compound with minimal detection in the cytoplasm (Figure 10A and 3A). Synchronized Gi / S-phase DLD1 cells, upon release from aphidicolin (APH) and treatment with NYH002, exhibited high accumulation of yH2AX foci when progressing into S-phase (Figure 10B-E and 3B). In contrast, CDK1 (RO-3306) inhibitor synchronized G2 / M-phase DLD1 cells which were subjected to the same treatment condition and transitioning into Gi-phase showed negligible DNA strand breakages. Furthermore, DNA fiber combing demonstrated a lack of ongoing replication and increased fork stalling (Figure 10F and 3C). This series of findings provides compelling evidence that NYH002 acts in proximity to the replication machinery to facilitate fork collapse.

[0184] We therefore conducted high-throughput chromosome conformation capture (Hi-C) sequencing on NYH002-treated DLD1 cells to examine structural abnormalities in chromatin organization to delineate the mechanisms underlying replication dynamics disruption. In each of the depicted gene sets, alterations in topologically associating domains (TADs) at their transcription start sites (TSSs) remained unchanged, except for the downregulated gene set (Lost <1), which exhibited a gain in chromatin interactions (Figure 3D). The high-contact-frequency chromatin compaction is restricted to short genomic distances, such as those identified in NFKB1 locus where there was a shift in loop interaction (Figure 3E-F). These condensed nuclear regions, marked by H3K27me3 expression (Figure 3G), could be a direct consequence of RNA polymerase II (RNAPII) stalling caused by transcription-replication conflicts (TRCs). To this end, immunoblotting of NYH002-treated DLD1 cells confirmed the retention of RNAPII, which also coincided with the induction of DNA DSBs and chromatin condensation, as evidenced by yH2AX activation and increased HP1 expression, respectively (Figure 3H).

[0185] NYH002 likely triggers TRCs through its ability to promote the formation of RNA:DNA hybrid structures (Figure 10G-H and 3I). To test this hypothesis, we examined the spatial proximity between the transcription machinery and replication fork collapse by assessing the co-localization of RNAPII and yH2AX foci, respectively in NYH002-treated DLD1 cells (Figure 3J). In line with this approach, transcription inhibition using DRB significantly reduced replication-dependent DSBs, which is consistent with TRC-driven DNA damage in response to NYH002 treatment (Figure 3K). The TRC-dependent DSB-induced genome instability raised the question of whether R-loop removal would disrupt NYH002's mechanism of action. Hence, DLD1 and H1299 cells were transduced with a RNaseHI -expressing vector to catalyze the cleavage of ribonucleotides in R-loop substrates, followed by NYH002 treatment. We observed that RNaseHI -expressing cancer cells exhibited a marked reduction in yH2AX foci accumulation after NYH002 treatment, which was accompanied by improved overall survival, as revealed by the higher ECso of NYH002 (Figure 101 and 3L-N).

[0186] NYH002 Targets R-Loop Dynamics by Modulating interleukin enhancer binding factor 2 (ILF2)-Dependent Helicase Function

[0187] By disrupting R-loop resolution, NYH002 promotes unresolved pathological RNA-DNA hybrids that directly obstruct replication fork progression. Our findings indicate NYH002 targets a core resolving factor critical to maintaining R-loop homeostasis. Hence, we conducted a competitive binding assaypairing NYH002 (antagonist) with its biotinylated derivative (NYH002P, interactor) to identify this target of interest (Figure 11A and 4A). Our data revealed a single high-affinity protein interactor between 48 kDa and 35 kDa in molecular weight (Figure 4B). This unidentified high-affinity (core) interactor of NYH002P, along with the remaining proteins (associate interactors), was subjected to LC-MS / MS analysis to determine the composition of the protein complex. (Figure 11 B). Peptide identification revealed a total of 795 interacting proteins. However, only 183 of these interacting proteins corresponded to the expected molecular weights of the excised silver-stained gel band regions (Figure 11 C and 4C). We then leveraged the core and associated interactors to sequentially map protein-protein interactions (PPIs) based on reference nuclear complexes from the CORUM database. The annotation strategy revealed a distinct interaction network enriched in DNA / RNA-binding proteins and transcription regulators (Figure 11 D and 4D).

[0188] Immunoprecipitation of NYH002P utilizing whole cell lysate (WCL) was conducted to investigate all uniquely identified DNA / RNA-binding and transcription-related proteins, including one representative each from the translation cluster and heterogeneous nuclear ribonucleoproteins. The analysis uncovered a novel protein complex composed of eight distinct members (Figure 11 E and 4E-F). Independent assessment based on amino acid sequence among the eight candidate proteins confirmed a high confidence interacting complex (Figure 11 F and 4G). Notably, the molecular weights of ILF2, YB1 , and HuR were consistent with the earlier unidentified immunoblot band range (<48 kDa and >35 kDa), positioning these proteins as plausible core interactors of NYH002. In a follow-up assessment using the proximity ligation assay (PLA) to establish spatial proximity within the uncharacterized complex, ILF2 emerged as the primary interacting partner of NYH002P (Figure 11G-H and 4H). The cellular thermal shift assay (CESTA), which evaluates protein thermostability in the presence of drug binding, provided further confirmation of the physical interaction between ILF2 and NY002 (Figure 4I).

[0189] Accordingly, we investigated the mechanism NYH002 modulates ILF2 activity to disrupt the stability and assembly of the protein complex. Immunoblot analysis revealed that the treatment with NYH002 did result in a coordinated downregulation of all members of the complex, a pattern that was recapitulated upon ILF2 knockdown via siRNA (Figure 4J-K). Notably, ILF2 depletion in DLD1 cells alone was sufficient to recapitulate phenotypic features of NYH002’s mechanism, namely the accumulation of unresolved R-loops and the displacement of single-stranded (ss)DNA (Figure 4L-M). This series of phenotypic observations supports the role of ILF2 as a mediator of replication stress which ultimately led to fork collapse as evidenced by the accumulation of yH2AX foci (Figure 4N).

[0190] Despite ILF2 having been previously suggested in R-loop regulation, there were discrepancies regarding the molecular mechanism through which it acted. Evidence supporting ILF2 as a central facilitator in coordinating RNA / DNA-binding proteins to regulate R-loop emerged from our earlier PLA data. Building on this mechanistic insight, we investigated key RNA:DNA helicases known to mediate R-loop resolution. Interestingly, immunoblot analysis of NYH002-treated and ILF2-depleted DLD1 cells revealed similar downregulation effect of DExH-box helicase 9 (DHX9), Senataxin (SETX), and Werner syndrome helicase (WRN), all major helicases that are essential for maintaining R-loop homeostasis (Figure 4O-P). However, immunoprecipitation of NYH002P showed direct interaction with DHX9 but notwith SETX or WRN (Figure 4Q). PPI based on STRING analysis supported the argument that ILF2 regulates SETX and WRN through DHX9 interaction (Figure 4R). This prediction was corroborated by our immunoprecipitation and PLA results, which showed a direct interaction between DHX9 and both SETX and WRN (Figure 11 l-K and 4S). In contrast, ILF2 did not exhibit physical binding to either SETX or WRN (Figure 11L-M). These findings therefore reinforce the notion that NYH002 impairs R-loop resolution by targeting ILF2 (Figure 4T).[001911 NYH002 Demonstrates Therapeutic Potential in Both Monotherapy and Combination Treatment

[0192] Elucidating NYH002’s mechanism of actions reveals its potential as a concomitant therapy to enhance first-line DNA-damaging treatments by enhancing irreversible DNA strand breakages to trigger apoptosis, despite presence of an intact post-replication DNA repair system (Figure 12A). To test this rationale, we leverage the enhancement of RNA:DNA hybrid accumulation to exacerbate R-loop burden while simultaneously introducing non-toxic DNA lesions to promote replication stress. NYH002 in combination with clinically-approved chemotherapeutic agents - temozolomide (TMZ) and 5-fluorouracil (5FU), with methyl methanesulfonate (MMS) serving as a positive control for replication stress, demonstrated synergistic effects (Figure 5A). At sub-therapeutic concentrations that do not elicit DNA damage-mediated apoptosis, chemotherapeutic agents (TMZ, 5-FU, and MMS) were still capable of inducing replication stress-induced DSBs (Figure 5B-C). Similarly, treatment with NYH002 at approximately its EC25, which was chosen to avoid triggering apoptosis in DLD1 cells, resulted in minimal induction of yH2AX foci. In contrast, the combination of NYH002 with either TMZ, 5-FU, or MMS led to a pronounced accumulation of replication stress-induced DSBs and apoptosis, as evidenced by the high degree of unresolved yH2AX foci and elevated levels of cleaved caspase-3, respectively. These findings highlight a synergistic interaction between NYH002 and DNA-damaging agents in amplifying the apoptotic response beyond what is observed with either therapeutic agent alone. As a proof-of-concept to validate the clinical relevance of this concomitant therapeutic strategy, we investigated the most effective combination, TMZ and NYH002, at 25 mg / kg and 10 mg / kg, respectively, in an animal model. Administration of alternate-day treatment over the initial two-week period resulted in complete inhibition of tumor progression. Consequently, the concomitant treatment regimen of TMZ and NYH002 was extended for an additional seven weeks to determine the possibility of therapeutic resistance, during which no palpable tumor masses were detected (Figure 5D).

[0193] Current evidence supporting this concomitant therapeutic approach reinforces the notion that G1 / S checkpoint-deficient tumors, characterized by their intrinsic genetic susceptibility to replication-induced DSBs, are likely to exhibit heightened sensitivity to NYH002 monotherapy. The identification of predictive marker / s for G1 / S checkpoint deficiency (Figure 12B-C), demonstrated a strong correlation among CCNE1, E2F1, E2F2, and CDC25A genes (Figure 12D) which included their significance in stratifying patient prognosis (Figure 12E). Leveraging on the identification of CCNE1 and E2F1 as top predictive markers for NYH002 monotherapy in G1 / S checkpoint-deficient tumors as supported by their association with RB1 mutation (Figure 12F), we curated the Cancer Cell Line Encyclopedia (CCLE) database to identify tumor models exhibiting differential expression of both genes. To establish a pancancer model system, we selected two pairs of cell-lines for comparative analysis. The first pair-match,MCF7 and MDA-MB-436 cells, represents breast cancer as a lineage-specific tumor model. The second non-pair match, comprising glioblastoma U251 and osteosarcoma U2OS cells, will serve as a comparison across tumor types (Figure 12G). Together, these four cancer cell lines will establish a therapeutic framework for targeting Gi / S checkpoint deficiency in a pan-cancer context. Immunoblot analysis confirmed elevated expression levels of CCNE1 and E2F1 in MDA-MB-436 and U2OS cells (Figure 5E-F), which were consistent with a higher baseline of unresolved DNA damage associated with replication stress (Figure 5G-H). Upon treatment with increasing concentrations of NYH002, which targets R-loop resolution, both MDA-MB-436 and U2OS cells displayed sensitivity to the inhibitor, as indicated by the progressive accumulation of unresolved yH2AX foci (Figure 5I-J) and a positive S9.6 fluorescence signal (Figure 12H). Consequently, these checkpoint-deficient cancer cells, which were unable to efficiently resolve replication stress-induced DSBs, exhibited a significant reduction in overall survival (Figure 5K-L). In contrast, MCF7 and U251 cells, which possess a functional Gi / S checkpoint, displayed reduced sensitivity to NYH002 under identical treatment conditions. In these cancer cells, yH2AXfoci were efficiently resolved despite increasing concentrations of NYH002. Furthermore, MCF7 and U251 cells showed better treatment tolerance, as reflected by higher EC50 values, highlighting the vulnerability of Gi / S checkpoint-deficient cells to NYH002 therapy.

[0194] NYH002 Exploits DNA Repair Vulnerabilities to Unmask Therapeutic Potential in Homologous Recombination Deficient Cancers

[0195] The marked difference in therapeutic sensitivity of Gi / S checkpoint-deficient cancer cells to NYH002, compared to their counterparts with functional cell cycle checkpoint, likely reflects a compromised DDR. Such impairment reduces cancer cells’ ability to repair replication stress-induced DSBs induced by NYH002. By analyzing a curated cohort of 9,880 solid tumors in a pan-cancer setting, we established a positive correlation between high CCNE1 and E2F1 expression and the presence of 70 and 34 mutated DDR genes, respectively (Figure 13A-B). In contrast of this observation, differential expression of CCND1 and CDK4, which governed the Gi-phase cell cycle progression did not correlate with DDR mutations (Figure 13C-D). Venn diagram analysis illustrated that 31 genes were common between high expressing CCNE1 and E2F1 (Figure 13E-I). Using this common DDR gene set, pathway enrichment concluded that most Gi / S checkpoint-deficient tumors had a limited HR repair capacity (Figure 13J-K). Hence, we investigated the context of pathway lethality by performing a loss-of-function analysis using a siRNA library that targets the DDR cascade (n = 239). This independent yet unbiased approach enabled a systematic evaluation of the functional contributions of key genes within the DDR network. Our findings identified 209 knockdown genes that conferred selective vulnerability to NYH002-treated DLD1 cells, with the majority implicated in the response to DSBs (Figure 6A-B). Pathway enrichment using the top 90th percentile of DDR genes revealed a critical role of HR in cancer cell’s survival (Figure 6C). Recognizing the pivotal role of a limited post-replicative repair mechanism in mediating susceptibility to NYH002 treatment, we investigated the top three candidate HR genes, exonuclease 1 (EX01), mutS homolog 3 (MSH3) and flap structure-specific endonuclease (FEN1) that were identified by the siRNA DDR library for synthetic lethal interaction (Figure 13L and 6D). Here, we moved beyond the reliance on breast cancer (BRCA) 1 / 2 mutations and utilized genomic scar assessment (Figure 13M) to capture a broader spectrum of HR deficiencies (37). Using a cut-off scoreof <42, we interrogated the CCLE database to identify representative cancer cell lines from each major solid tumor type exhibiting HR proficiency (38, 39). An HR-deficient (HRD) cell line (score >42) was included as a negative control (Figure 13N). Notably, siRNA-mediated depletion of EX01, MSH3, or FEN1 exacerbated NYH002 sensitivity (approximately EC25) in all HR-proficient cancer cell lines, resulting in near-complete ablation of cell growth (Figure 6E). This effect was, however, absent in the HRD CAPAN-1 cell line, which had already exhibited pre-existing susceptibility to NYH002. Further depletion of EX01, MSH3, or FEN1 did not exacerbate growth inhibition in NYH002-treated CAPAN-1 cells.

[0196] In our preclinical assessment, we identified and selected the most frequent occurring HRD tumor type in the CCLE dataset as a representative model to investigate the therapeutic potential of NYH002 in targeting solid tumors with deficient HR (Figure 13O-P). Based on this analysis, we prioritized on lung and breast cancers. Clonogenic and cell viability assays confirmed that H1299 (lung) and MDA-MB-436 (breast) cells with HRD exhibited significant vulnerability to NYH002 therapy, whereas their HR-proficient counterparts, A549 and MDA-MB-231 , exhibited better tolerance under identical treatment conditions (Figure 13Q and 6F). Our dose escalation assay in non-tumor bearing animals determined that 25 mg / kg of NYH002 represents the relative minimum effective dose with complete drug clearance observed by 24 hours (Figure 13R and 6G). Intraperitoneal administration of NYH002 at this concentration led to widespread distribution across all major organs within six hours, as confirmed by LC-MS / MS. Given the molecular weight of NYH002 is approximately 450 Da, the ability of this small molecule to penetrate the blood-brain barrier is consistent with its physicochemical properties (Figure 6H). Importantly, there was no adverse and chronic systemic cytotoxicity even after two weeks of intraperitoneal administration and this finding was corroborated by stable blood counts (Figure 6I) and an absence of cell death, as confirmed by H&E staining of the liver and kidney (Figure 6J-K). Across the four xenograft models encompassing both HRD and HR-proficient subtypes of lung and breast cancer, administration of NYH002 at a dosage of 25 mg / kg consistently reduced tumor growth in all animals (Figure 6L-O). Its therapeutic efficacy, however, was remarkable in HRD tumors, where growth was abrogated, highlighting NYH002’s selective cytotoxicity against malignancies with compromised HR (Figure 13S-T).

[0197] EXAMPLE 4. DISCUSSION

[0198] There is an elegant symmetry between transcription and replication, where one decodes the genome while the other duplicates the DNA. Both processes are choreographed with remarkable spatial separation to ensure a harmonious interplay that does not compromise genome integrity. Oncogenic signalling on the other hand drives cancer cells into a state of hyper-transcription, increasing nascent RNA production to fuel uncontrolled proliferation at the consequence of fostering R-loops formation. These RNA:DNA hybrids are transiently formed within the active site of RNA polymerase when nascent RNA anneals to the template DNA strand and displaces the non-template strand, thus creating a three-stranded structure that is readily resolved upon the release of RNA. R-loops when left unregulated can obstruct advancing replication forks particularly in regions of the chromatin where transcription and replication machineries frequently converge, leading to TRCs. Collisions between these two elements provoke replication stress, establishing an endless cycle of DNA damage-induced mutagenesis andtumor evolution. Paradoxically, excessive presence of R-loops pushes cancer cells toward a precarious state of overwhelming DNA damage, forcing them to rely on an overburdened post-replication repair system such as homologous recombination (HR) for survival. The reliance on pathological R-loops to provoke replication stress-induced mutation and accelerate malignant progression is an exploitable vulnerability.

[0199] Therapeutic strategies that augment R-loop accumulation by disrupting their resolution can potentiate replication stress-induced DNA breakage through head-on TRCs. Although compounds such as romidepsin (HDAC inhibitor) and camptothecin (TOP1 inhibitor) have been proposed to enhance R-loop formation, they were not originally developed to target R-loop biology. Rather, romidepsin and camptothecin ability to induce RNA:DNA hybrids arise as an indirect consequence of their primary mechanism of action. As of now, there are no clinically approved R-loop inducing drugs. Regardless of the strategies being employed, the deliberate objective is to surpass the DNA damage threshold essential for genomic stability and ultimately forcing a state of replication catastrophe. Persistent genomic stress can transform a tumorigenic mechanism into a lethal weakness. The resulting unresolved DNA DSBs offer a strategic basis for the selective elimination of cancer cells while sparing normal tissues with inherently low replication stress.

[0200] Here, we uncover a previously uncharacterized role of ILF2, which functions in concert with different helicases to resolve R-loop formation. Targeted inhibition of this pathway by derivatized Molephantins induces selective cytotoxicity in cancer cells exhibiting Gi / S-phase dysregulation, especially those with a compromised HR repair. Our discovery reveals insight into both the role of the ILF2 complex in preserving genomic stability and a therapeutic paradigm that exploits vulnerabilities in cancer-specific stress mitigation pathways to enhance targeted therapies.

[0201] R-loop represents a fundamental paradox in tumor malignancy, indispensable for cellular functions, yet lethal in excessive amount. Their threat to genome integrity arises when R-loops drive TRCs, a context that motivated the discovery of ILF2’s critical role in safeguarding replication stress-induced DNA DSBs. While replication and transcription are mechanistically distinct and temporally separated processes, they are frequently converged on the same genomic locus. Precise coordination of R-loop resolution is essential to prevent deleterious head-on collisions between transcription machinery and advancing replication forks. The fidelity of DNA replication during active transcription is dependent on ILF2 interaction with various helicases. By direct binding with ILF2, helicases such as DHX9 can actively unwind stable RNA:DNA hybrids and assist RNAPII in engaging template DNA to initiate nascent transcripts synthesis. This finding is consistent with our observation in the reduced activities at TSSs and the stalling of RNAPII from unresolved R-loops. Like DHX9, other helicases including SETX and WRN also play an immediate role in the unwinding of RNA:DNA hybrid structures. BRCA1 and USP11 are known recruiters for SETX, analogous to CK2 in activating WRN to initiate R-loop resolution. Current evidence is clear that each helicase is subject to distinct regulatory mechanisms, underscoring their independent roles in R-loop resolution. Conversely, emerging data also demonstrated a multitude of these helicases are conserved and can act in concert through direct interaction with each other to ensure timely resolution of R-loop. It is possible independent pathwaysthat regulate different helicases are necessary for redundancies, but the understanding of how these different mechanisms cooperate to maintain R-loop homeostasis remain incomplete.

[0202] Our work offers an alternative model in which ILF2 overrides these individual pathways by acting as a central regulator. Depletion of ILF2 triggers a cascade of protein destabilization via DHX9, including SETX and WRN, while also impacting members of the DEAD / DEAH-box RNA helicases; DDX3X, DDX5, and DHX15. ILF2’s ubiquitous expression and near absence of somatic mutations argue against a classical oncogenic role. Instead, ILF2 acts as a non-oncogenic factor, leveraging its upstream regulatory function in R-loop resolution to mitigate genomic stress driven by TRCs.

[0203] The exploitation of ILF2’s role as a central regulator of RNA:DNA helicases led to the discovery of NYH002 as a first-in-class ILF2 inhibitor (Figure 7A). NYH002-treated cancer cells phenocopy ILF2 depletion by disrupting the signalling network essential for R-loop resolution. Several helicase inhibitors have been developed. Their therapeutic application is however hindered by their essential roles in RNA and DNA metabolism, complicating efforts to selectively target R-loop resolution without disrupting other critical cellular processes. Inhibiting ILF2 as the central regulator coordinates the removal of all downstream RNA:DNA helicase activities dedicated to R-loop resolution and enables a precise targeting without compromising other helicase-associated pathways. Additionally, our PK and biodistribution assessment demonstrated that the serum concentration required for NYH002 to impede tumor progression is readily achievable without chronic adverse side effects. An independent phenotypic study corroborated our findings, confirming that Molephantin exerts selective cytotoxicity against high-grade cancers. These results align with the retrospective observational data, where cancer patients undergoing integrative medicine did not exhibit long-term systemic therapeutic toxicity. Instead, routine medical assessments and patient-reported outcomes concluded stable disease or tumor reduction.

[0204] The stark contrast in NYH002's therapeutic cytotoxicity in eliminating tumorigenic cells and leaving minimal harm on healthy tissue can be explained by modeling cell cycle checkpoint progression (Figure 7B). Tumors with Gi / S deficiency have considerable replication stress. When NYH002 disrupts DNA replication by introducing unresolved R-loops, these tumors encounter an increased frequency of TRCs, leading to replication stress-induced DNA breakages. Repair of these S-phase DSBs is initiated by DNA end resection, a process that biases toward HR and compels NYH002-treated tumors to rely on this post-replicative DSB repair pathway for survival. We exploited the dependency of HR-mediated repair by combining NYH002 with different DNA damage inducing agents to exacerbate DSB accumulation beyond the threshold of repairability. To further examine this therapeutic strategy, we extended the investigation to uncover vulnerabilities in HRD cancer cells that are independent of BRCA1 / 2 status to broaden the treatment potential of NYH002. Our data present multiple lines of evidence indicating that the disruption of R-loop homeostasis constitutes a key determinant for selective killing in cancer cells. Here, Gi / S-deficient cancer cells are more vulnerable to NYH002 in triggering TRCs. Overexpression of RNaseHI counteracts NYH002-induced R-loop accumulation via RNA strand degradation, thereby rescuing replication stress-induced DNA breakages. The relationship of synthetic lethal HR gene pairs EX01, FEN1 and MSH3 in ILF2-depleted cells is substantiated across multiple solid tumor types. Lastly, NYH002 as a monotherapy suppresses tumor growth in both BRCA1 / 2-independent HR-deficient xenografts and BRCA1 / 2-mutant orthotopic models. Our findings inform a mechanistic framework that has been mirrored by emerging reports describing two individual synthetic lethality strategies; disrupting transcription factors to elevate R-loop accumulation in DNA repair deficient cells and promoting the displacement of exoribonucleases in cancers burdened by excessive R-loops. Collectively, our study positions NYH002 as an actionable therapeutic agent that leverages ILF2’s central role in R-loop resolution to eliminate HRD cancer cells, providing a distinct strategy beyond conventional DNA repair-targeted approaches.

[0205] Hidden beneath the layer of tumor malignancy lies unchecked proliferation driven by hyperactive transcription, which fosters the formation of RNA:DNA hybrids. These structural intermediates precipitate collisions between the transcription and replication machineries. Central to mitigating this genomic threat is interleukin enhancer-binding factor 2 (ILF2), which orchestrates the recruitment of RNA:DNA helicases to resolve R-loops and, in doing so, reveals cancer cells dependency on stress-mitigating mechanisms to avert genome catastrophe. Our discovery of Molephantin and its lead derivative, NYH0002 is the outcome of delineating ILF2’s function. NYH002 exerts direct binding to the ILF2 complex and disrupts RNA:DNA helicase activity to elicit genome-wide DNA breakages. Tumors with elevated cyclin E and E2F1 expression are sensitive to NYH002, while those deficient in homologous recombination repair exhibit lethality. Collectively, these findings position ILF2 as a key regulator of R-loop homeostasis and reveal a therapeutic vulnerability that NYH002 exploits to suppress tumor malignancy.

Claims

CLAIMS:

1. A method of treating a DNA damage response deficient cancer in a subject, the method comprises administering an effective amount of a compound of formula I, or a pharmaceutically acceptable salt or solvate thereof, to the subject,where R1and R2each independently represent H, -C(O)R3or -C(O)Ci-e alkyl, which latter group is unsubstituted or substituted by one or more groups selected from halo and R4, or R1represents -C(O)R3or -C(O)Ci-e alkyl, which latter group is unsubstituted or substituted by one or more groups selected from halo and R4, and R2represents -C(O)C(=CH2)CH3;R3, when present, represents aryl, cycloalkyl ora heterocyclic ring system, where each of aryl, cycloalkyl and the heterocyclic ring system is unsubstituted or substituted by one or more groups selected from halo, Ci-3 alkyl, and NO2, where C1-3 alkyl is unsubstituted or substituted by one or more halo groups;R4, when present, represents aryl, cycloalkyl ora heterocyclic ring system, where each of aryl, cycloalkyl and the heterocyclic ring system is unsubstituted or substituted by one or more groups selected from halo and C1-3 alkyl, where C1-3 alkyl is unsubstituted or substituted by one or more halo groups.

2. The method of claim 1 , wherein the compound is selected from the group consisting of:

3. The method of claim 1 or 2, wherein the DNA damage response deficient cancer is a homologous recombination (HR) deficient cancer.

4. The method of claim 3, wherein the HR deficient cancer has an HR deficiency score.

5. The method of claim 4, wherein an HR deficiency score of at least 42 indicates a HR deficient cancer.

6. The method of claim 1 or 2, wherein the DNA damage response deficient cancer is a Gi / S checkpoint deficient cancer.

7. The method of any one of claims 1 to 6, wherein the cancer exhibits elevated cyclin E expression and / or elevated E2F1 expression, optionally wherein the cyclin E is CCNE1.

8. The method of claim 1 or 2, wherein the DNA damage response deficient cancer is a HR proficient cancer characterized by deficiency in one or more of EXO1 , MSH3, and FEN1.

9. The method of claim 1 or 2, wherein the DNA damage response deficient cancer is characterized by a defect in one or more genes selected from the group consisting of APTX, ATRIP, BARD1 , BLM, CHK1 , CHK2, DMC1, ETAA1 , FBH1 , LIG1 , LIG4, NBN, PALB2, PARP1 , PARP2, POLD1 , POLD2, RAD18, PRAD51D, RMI1, RPA1 , RPA2, RTEL1 , SETMAR, SHLD2, SLX4, SPIDR, TDP1 , UIMC1, XRCC4, XRCC6, ATR, P16, P21 , E2F1 , E2F2, RB1 , PTEN, MRE11 , RAD50, and RAD51.

10. The method of any one of claims 1 to 9, wherein the cancer is a solid tumor.

11. The method of any one of claims 1 to 10, wherein the cancer is selected from the group consisting of lung cancer, breast cancer, stomach cancer, ovarian cancer, liver cancer, colorectal cancer, brain cancer, pancreatic cancer, prostate cancer, and bone cancer.

12. The method of claim 11 , wherein the cancer is lung cancer or breast cancer.

13. The method of any one of claims 1 to 12, further comprising administering one or more additional anticancer agent.

14. The method of claim 13, wherein the additional anticancer agent is a DNA-damaging agent.

15. The method of claim 13 or 14, wherein the additional anticancer agent is an alkylating agent.

16. The method of any one of claims 13 to 14, wherein the additional anticancer agent is selected from the group consisting of temozolomide, methyl methanesulfonate, and 5-fluorouracil.

17. The method of any one of claims 1 to 16, wherein the subject has not previously received first-line anti-cancer therapy.

18. The method of any one of claims 1 to 16, wherein the subject has previously received first-line anticancer therapy.